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ABSTRACT 
 
Cell-penetrating peptides (CPPs) are short amino acid sequences, consisting of 
up to 30 amino acids, capable of delivering bioactive cargos inside cells in an 
efficient and non-toxic fashion. Several cellular internalization pathways have 
been proposed for these molecules and the majority of studies conclude that 
CPPs utilize several uptake routes simultaneously with some favored more than 
others. The reports vary as internalization depends on the type and concentra-
tion of the CPP, the nature of the cargo, the specific cell membrane composition 
of the studied cell line, the intracellular target and other experimental condi-
tions. In the present thesis, uptake mechanisms of several common CPPs are 
characterized by studying their cytosolic uptake kinetics using fluorescent and 
bioluminescent cargos. In addition, transfection mechanisms of non-covalent 
CPP-oligonucleotide nanocomplexes are investigated by assessing the effects of 
hydrophobic CPP modifications and complex formation on their efficacy. 
 We utilized kinetic assays to determine the simultaneous involvement of se-
veral uptake pathways in CPP internalization. The chosen peptides displayed 
very different and concentration dependent uptake kinetic profiles that were 
strongly affected by endocytosis inhibitors. Both of the studies support the 
simultaneous involvement of several endocytotic pathways in their cellular up-
take. To study the hydrophobic effects on transportan 10 mediated splice-cor-
recting antisense oligonucleotide delivery, we conjugated different fatty acids to 
the peptide and measured how these modifications affect the hydrodynamic size 
and transfection efficacy of CPP-oligonucleotide complexes. We determined the 
optimal hydrophobic CPP modification and nanocomplex size for maximal 
splice correction efficiency. In order to elucidate the role of complex formation 
in CPP-mediated siRNA transfections, we utilized isothermal calorimetry in 
conjunction with dynamic light scattering studies. The results revealed that 
although the complexes are with the same size at acidic and physiological pH, 
the amount of CPPs in the nanocomplexes varies, indicating that the dynamic 
equilibrium between the peptides and the cargo is pH-dependent. 
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INTRODUCTION 
In order to successfully utilize the vast number of available potential drugs in 
clinical settings, they need to reach their required target. More often than not, 
this requires an efficient and safe delivery vector. Cell-penetrating peptides 
(CPPs) are a class of non-viral delivery vectors that meet these criteria. 
As of today, more than one hundred CPPs are available with varying 
physicochemical properties and internalization mechanisms. In order to sift out 
the most effective delivery vectors, their exact uptake mechanisms, kinetics and 
cargo delivery properties need to be determined. 
Kinetic uptake studies coupled with endocytic pathway studies enable to 
determine the involvement and extent of each uptake route in CPP internali-
zation in a more transparent fashion compared to single-endpoint methods. We 
therefore assessed the cytoplasmic uptake kinetics and mechanisms of several 
common CPPs using a quenched fluorescence assay and a semi-biological 
bioluminescence assay. 
Physicochemical studies of CPP-cargo complexes can reveal the uptake 
mechanisms of these dynamic non-covalent conjugates that can be used in the 
further development of more potent delivery vectors. We assessed the role of 
CPP hydrophobicity in the delivery of splice-correcting antisense oligonucleo-
tides (SCOs). In addition, we characterized the interactions between CPPs and 
siRNA to shed light on their transfection mechanism. 
The results presented in this thesis exemplify the advantage of kinetic assays 
as well as the importance of studying the physicochemical properties of non-
covalent CPP-oligonucleotide nanocomplexes in understanding CPP and CPP-
cargo uptake mechanisms. This thesis brings out crucial aspects that have to be 
accounted for when designing novel delivery vectors for biotechnological and 
clinical applications. 
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1. LITERATURE OVERVIEW 
Advances in biochemistry and molecular biology over the years, together with 
the human genome sequencing project, have increased our understanding of the 
genetics of numerous diseases and has led to the identification of many disease-
causing genes. In order to treat these diseases by inhibiting, modulating or intro-
ducing new genes to the affected cells, appropriate drugs need to be transported 
into their point of action. Due to their physicochemical properties, many drugs 
are unable to enter cells and require delivery vectors which are efficient, safe, 
and resistant to degradation. Generally, there are two types of vehicles, viral and 
non-viral. The most studied non-viral delivery vectors are liposome-, polymer- 
and micelle- based systems, and more recently, cell-penetrating peptides (CPPs) 
have gained interest as well. 
 This thesis concentrates on the cellular internalization mechanisms and CPP 
uptake kinetics characterization of CPP and CPP-cargo conjugates. 
 
1.1 Cell-penetrating peptides (CPPs) 
CPPs are short peptide sequences consisting of up to 30 amino acids that are 
able to cross the cellular membrane and transport bioactive cargos into cells in a 
non-toxic and efficient fashion. CPPs generally are positively charged and 
amphipathic, possessing both hydrophilic and lipophilic properties, enabling 
them to interact both with cargos and the cell membrane. 
 
1.1.1 CPP origins 
The inception of the CPP field is closely related to the finding that full length 
HIV-1 transcription transactivation (Tat) protein [1] and Drosophilia Antenna-
pedia homeodomain [2] were shown to be able to translocate to the interior of 
cells and accumulate in the cell nucleus. This led to the discovery of protein 
transduction domains (PTDs), launching the field of CPPs. The first CPPs 
penetratin [3] and Tat [4] were exclusively derived from naturally occurring 
transport proteins. However, later many novel CPPs with chimeric nature, such 
as MPG [5], Pep-1 [6] and TP10 [7] or of completely designed amino acid 
sequences, such as polyarginines [8, 9], YTA-2 and YTA-4 [10], MAP [11] and 
CADY [12], have been proposed. 
 
1.1.2 CPP classification 
CPPs can be classified according to their origin or chemical properties, such as 
their charge, hydrophobicity or amphipathicity. Classification by origin, as 
exemplified in the previous chapter, focuses more on CPP evolution and is 
therefore less informative. In order to study CPP cellular internalization mecha-
nisms, the peptides need to be categorized based on their structural and che-
mical properties. As a result, CPPs can be divided into cationic, hydrophobic 
and amphipathic peptides (Table 1). 
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Table 1. Examples of common CPP by classification. 
CPPs Origin Sequence Ref. 
Cationic    
R9 Designed RRRRRRRRR [8] 
RxR Designed RxRRxRRxRRxR [13] 
Tat HIV-1 transactivator protein GRKKRRQRRRPPQ [4] 
Hydrophobic 
SG3 Plasmid selection RLSGMNEVLSFRWL [14] 
Pep-7 Phage display SDLWEMMMVSLACQY [15] 
KF Kaposi fibroblast growth factor AAVALLPAVLLALLAP [16] 
Primary amphipathic 
TP10 Galanin and Mastoparan AGYLLGKINLKALAALAKKIL [7] 
Secondary amphipathic 
Penetratin Antennapedia homeodomain RQIKIWFQNRRMKWK [3] 
MAP Designed KLALKLALKALKAALKLA [11] 
CADY Chimeric peptide PPTG1 GLWRALWRLLRSLWRLLWRA [12] 
pVEC Murine VE-cadherin LLIILRRRIRKQAHAHSK [17] 
EB1 Chimeric LIRLWSHLIHIWFQNRRLKWKKK [18] 
Proline-rich 
SAP Designed VRLPPPVRLPPPVRLPPP [19] 
x-aminohexanoic acid 
  
 
Typical cationic CPPs, R9 [8], Tat [4] and (RxR)4 [13, 20] all possess a high 
positive net charge and no acidic amino acid residues. Although the number of 
arginine residues can vary, studies suggest that at least six positive charges are 
required to induce efficient CPP uptake [21]. These peptides interact with 
anionic cell membrane constituents such as glycosaminoglycans and rely less 
on interactions with membrane lipids [22, 23]. Arginine-rich peptides were ini-
tially considered as the “Trojan horse” delivery vectors that enter cells without 
eliciting any adverse cellular responses [24]. Nevertheless, later studies have 
shown that these CPPs can induce a wide range of side-effects, including 
reduced membrane integrity and cell viability [25]. 
 CPPs containing only apolar residues can be classified as hydrophobic and so 
far only a few have been discovered, such as the signal sequence from Kaposi 
fibroblast growth factor [26] and SG3, a CPP identified by a plasmid display-
based selection platform [14]. However, hydrophobic amino acid residues are 
crucial in case of many amphipathic and other long chimeric CPPs. 
 One of the most informative methods of CPP classification is based on their 
physicochemical properties. Peptides, such as TP10 [27], contain both polar and 
non-polar regions and are categorized as primary amphipathic CPPs. The hydro-
phobic character of these CPPs has been shown to be responsible for their 
cellular internalization mechanism as indicated by their affinity to both neutral 
and anionic lipid membranes [22, 28, 29]. However, the interaction between the 
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cell membrane and these CPPs is strongly dependent on the membrane potential 
and composition [30], as primary amphipathic peptides can induce concent-
ration dependent leakage in model membranes and often lyse bacteria without 
affecting eukaryotic cells [31]. 
 Secondary amphipathic CPPs have a highly hydrophobic region on one face 
of the peptide while the other face may be cationic, anionic or polar. Common 
examples include penetratin [3], MAP [11], CADY [12] and pVEC [17]. These 
peptides maintain a random coil structure in solution but adapt an α-helical or in 
some cases β-sheet structure once in contact with cell membrane components, 
such as glycosaminoglycans and lipids. Secondary amphipathic CPPs interact 
weakly with neutrally charged membranes and bind to cell membranes which 
contain at least 20% anionic lipids [22, 32], with the possible exception of 
MAP, which causes membrane leakage at high concentrations [33, 34]. 
 Another class of amphipathic CPPs is proline-rich peptides, which contain a 
proline or pyrrolidine template and exhibit self-assembly properties [19]. 
 
1.1.3 CPPs in cargo delivery 
Cargos can be conjugated to CPPs covalently or complexed non-covalently. 
Generally, in order to attain the desired biological effect, once internalized, the 
cargo needs to be released. To achieve this in case of covalent CPP-cargo 
conjugates, biodegradable linkers have to be used. One of the most commonly 
used strategies is conjugation through a disulfide linker [35–38], as it remains 
sufficiently stable in the extracellular media and is cleaved once reaching 
reducing intracellular compartments, particularly the cytosol [39, 40]. In addi-
tion, disulfide bond cleavage in endosomes and lysosomes is very inefficient as 
endocytotic pathways are oxidizing [40]. However, evidence suggests that in 
some cases disulfide cleavage can also occur on the cell surface [36] and 
therefore it is important to observe the free thiol contents in the extracellular 
environment when utilizing disulfide linkers. Examples of successful covalent 
CPP-cargo conjugates include peptides [41], proteins [42], chemotherapeutics 
[43] and oligonucleotides (ONs) [35, 44]. Because the negatively charged 
oligonucleotides can mask the positive CPP charges and render the conjugate 
ineffective [45, 46], in covalent conjugation strategies, uncharged ON analogues 
such as peptide nucleic acids (PNAs) and phosphorodiamidate morpholino 
oligonucleotides (PMOs) have to be utilized as cargos [47, 48]. 
Non-covalent CPP conjugation strategy can be used virtually for any negati-
vely charged molecule and it has been widely applied for short splice-correcting 
antisense oligonucleotides (SCOs), small interfering RNAs (siRNAs) and large 
plasmid DNA (pDNA). The benefits of non-covalent complexation are conve-
nient sample preparation, easily variable CPP-to-cargo ratios and that the 
intrinsic activities of both CPPs and cargo are preserved. These nanocomplexes 
can also be easily modified with additional targeting and/or shielding moieties. 
However, there are limitations associated with the use of non-covalent comple-
xes in vivo. The CPP-cargo nanocomplexes have to be resistant to degradation 
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and clearance and reach the target site in sufficient doses. Therefore, clinical 
applications might be limited to local administration [49]. 
 
1.1.4 Evolution of CPPs 
In order to utilize CPPs as effective cellular delivery vectors they have to 
associate with cargo molecules optimally, so that the complexes are intact in the 
extracellular medium and dissociate once taken up by endosomes and enable the 
release of the cargo into cells. CPPs also have to be resistant to degradation by 
serum enzymes but at the same time remain non-toxic. The systemic toxicity of 
certain CPPs could be reduced by improving their cell or tissue specificity, 
thereby decreasing required effective concentration [50]. 
 Covalent conjugation strategies have been used more frequently for cargo 
delivery as most peptides are not able to condense cargo into nanocomplexes 
and/or subsequently release it from endosomes. In case of non-covalent con-
jugates, mainly three types of interactions occur between positively charged 
CPPs and negatively charged oligonucleotides – electrostatic, hydrophobic and 
hydrogen bonding. In order to develop efficient delivery vectors, all of these 
properties have to be optimized. For example, stearoylation of octaarginine 
increases its plasmid transfection efficiency by approximately 100-times [51].  
 However, the major issue for novel CPP delivery vectors remains endosomal 
escape, as most studies indicate endocytosis as the dominant internalization 
route for non-covalent CPP complexes. A common method for overcoming 
endosomal entrapment is co-incubation of cargo complexes with the endoso-
molytic agent chloroquine [52]. Recently, this rationale was used for the 
development of a highly potent CPP, PepFect6 (PF6), by incorporating chloro-
quine analogues in its chemical structure [53]. PF6 was additionally modified 
with a fatty acid which could contribute to endosomal membrane disruption [54, 
55]. Hydrophobic modifications could also increase the CPPs resistance to 
proteases and peptide stability can be further increased by using D-form or 
unnatural amino acids [56, 57]. Some CPPs, such as KALA [58] and EB1 [18] 
can also display inherent endosomolytic properties as their conformation adapts 
to changes in pH as they are transported to acidic endosomal compartments. 
 In order to enhance the clinical applicability of CPPs, they should be cell- or 
tissue type-specific. This can be achieved by adding targeting moieties such as 
certain amino acid sequences to CPPs. For example, rabies virus glycoprotein-
derived peptide is capable of crossing the blood-brain-barrier [59] and CendR 
peptides internalize into cells and bind to the tumor cell-specific receptor 
neuropilin-1 [60]. Numerous other targeting ligands have been tested over the 
years with some showing great promise [61]. 
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1.1.4.1 Hydrophobic modifications 
As mentioned in the previous chapter, the first successful hydrophobic modi-
fication in the CPP field was stearoylated octaarginine. The improved trans-
fection efficiency can be a result of increased CPP-oligonucleotide binding as 
described in case of stearoylated cationic polyaspartamide derivatives that dis-
played more effective siRNA condensation and siRNA mediated gene knock-
down than their non-stearoylated parent peptides [62]. In addition, hydrophobic 
moieties might be exposed on the surface of the formed nanoparticles and there-
by contribute to the absorption of the complexes on the cell membranes and the 
subsequent disruption of endosomal membranes. Hydrophobic fatty acid chains 
could also increase resistance against serum degradation [63]. 
 Fatty acid modifications have improved the cargo delivery properties of 
numerous CPPs. For example, stearoylation highly increased the SCO trans-
fection efficiency of (RxR)4 and TP10 peptides [13, 64], however several 
reports indicate that the optimal length of the fatty acid modification can differ 
between CPPs. Therefore numerous different fatty acids have been tested in 
conjunction with this strategy. For Alexa-labelled octaarginine, a hexanoyl 
modification showed the highest efficiency of cellular uptake of the studied 
variants [65] and in case of an anti-proliferative somatostatin analog, pamitoy-
lation significantly increased its activity [63]. Also, addition of capric acid to 
human calcitonin derived CPPs resulted in efficient cytosolic delivery of 
siRNA. The developed vectors were used for knockdown of the G protein-
coupled human neuropeptide YY1 receptor [66]. Another fatty acid, laurylic 
acid, combined with the use of D-amino acids, was shown to increase the 
cellular uptake of oligoarginines. These CPPs efficiently internalized to the cells 
and exerted low cellular toxicity, however, if lacking the lipid chain, peptides 
were degraded and transported out of the cells [67]. The lauroyl modification 
was chosen based on the screening of several fatty acid modifications stressing 
the need for an optimal fatty acid length [68]. Recently a series of highly potent 
stearoylated CPPs, NickFects and PepFects, were developed that are able to 
deliver various nucleic acids inside cells [53, 69–71]. 
 In paper I, the effect of twelve different hydrophobic modifications on TP10 
mediated splice-correcting antisense oligonucleotide delivery was investigated. 
 
1.2 CPP internalization mechanisms 
Ever since the introduction of the first CPPs, penetratin and Tat, more than 100 
CPPs have been developed [61]. These peptides can possess very different 
physicochemical properties and have therefore shown to utilize various cellular 
internalization mechanisms (Figure 1). 
Studying the mode of action of all types of CPPs involves registration of 
cellular entry after inhibiting certain cellular entry pathways. Most studies con-
centrate on affecting endocytic pathways by either chemical inhibitors, knocking 
down selected genes responsible for certain endocytotic routes, or by simply 
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lowering the temperature to where active transport processes are stopped. From 
these types of studies it has been concluded that generally CPPs are taken up by 
several endocytotic pathways simultaneously with one path favored more than 
others in case of certain CPPs. Endocytosis is mainly triggered by interactions 
between the peptide and cell membrane constituents, such as negatively charged 
glycosaminoglycans and phospholipids. In addition, especially when attached to 
larger cargos, CPPs can utilize certain receptors in their uptake, such as class A 
scavenger receptors [70, 72]. As chemical modifications have to be introduced to 
CPPs in order to study their uptake, interpretations should be made in the context 
of the CPP and the cargo together. 
 
 
Figure 1. Cellular uptake mechanisms utilized by CPPs. Dynamin dependent 
clathrin- and caveolae-mediated endocytosis as well as dynamin independent macro-
pinocytosis and clathrin- and caveolae independent endocytosis pathways are all in-
volved in CPP uptake. The resulting vesicles are of different diameter in case of each 
pathway. Initial CPP uptake is followed by intracellular trafficking into a variety of 
endomembrane vesicular compartments including early/late endosomes and lysosomes. 
Endosomal escape of CPPs can occur at any point during this process. In addition, some 
CPPs destabilize the cellular membrane and are taken up by direct translocation, i.e. 
through inverted micelle- or pore formation. 
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1.2.1 Endocytosis 
Endocytic mechanisms can affect the lipid and protein composition of the 
plasma membrane, thereby regulating the transport of bioactive molecules into 
cells [73]. Classically, cellular uptake pathways are divided into endocytic path-
ways and non-endocytic pathways. Endocytosis is commonly said to consist of 
four types of pathways: phagocytosis, clathrin-mediated endocytosis (CME), 
caveolae-mediated endocytosis (CvME), macropinocytosis (MP) and clathrin- 
and caveolin independent endocytosis [74]. 
 Phagocytosis has generally not been associated with CPPs as it occurs only in 
macrophages, monocytes, neutrophils, and dendritic cells [75] whereas CME, 
CvME, and MP occur in almost all kinds of cells including the aforementioned 
[74, 76]. The phagocytic pathway is mediated by cup-like membrane exten-
sions, usually larger than 1 µm, to internalize large particles such as bacteria or 
dead cells. 
 
1.2.1.1 Clathrin-mediated endocytosis (CME) 
Clathrin-mediated endocytosis is the most-well studied endocytic pathway. It is 
receptor-dependent and requires clathrin proteins and the GTPase dynamin [77]. 
Its first step consists of coat nucleation mediated by the internalized molecules 
and phosphatidylinositol(4,5)-bisphosphate, PI(4,5)P2. During this process, 
cargo molecules are clustered and concentrated within the emerging clathrin 
coated pit with a size about 100–150 nm [78, 79]. As the clathrin lattice forma-
tion continues, the pit becomes deeply invaginated, until vesicle fission occurs, 
driven by the GTPase dynamin [77]. The next step in the CME pathway is 
transport of endocytosed vesicles from the vicinity of plasma membrane 
towards late endosomes and ultimately to lysosomes [80]. During endosome 
maturation from early endosomes to lysosomes, intraluminal pH is gradually 
being lowered by proton pumps. Once reaching lysosomes, endosomal cargo is 
enzymatically degraded [81]. Thus, therapeutic cargos must escape from endo-
somes to retain their biological activity and avoid degradation. 
 Clathrin consists of three clathrin heavy chains which are tightly bound to 
clathrin light chains [82]. During clathrin coat assembly the terminal domain of 
clathrin serves as a second protein-protein interaction hub that clusters AP-2 
and accessory proteins into a clathrin-centered interaction network [79]. To 
inhibit CME in the current thesis, hypertonic sucrose was utilized which is 
known to dismantle these clathrin structures. As sucrose modifies the actin 
cytoskeleton and can therefore induce cytotoxicity, a more specific CME 
inhibitor, chlorpromazine (Cpz) was used additionally. Cpz depletes the clathrin 
and AP2 adaptor protein complex from the plasma membrane to the endosomal 
membranes. 
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1.2.1.2 Caveolae-mediated endocytosis (CvME) 
CvME, also termed as lipid raft-mediated endocytosis, begins with the forma-
tion of a wedge-shaped structure by a scaffolding membrane protein, caveolin. 
CvME is a cholesterol, dynamin-dependent and receptor-mediated pathway [83] 
in the sense that caveolins, the structural proteins of caveolae, are a family of 
cholesterol-binding proteins. In addition, the fission of the caveolae from 
membranes is mediated by dynamin, which locates in the neck of caveolae and 
then generates the cytosolic caveolar vesicle, caveosome, with a diameter in the 
range of 50–100 nm [74]. Examples of receptors located in caveolae that can 
mediate CvME include insulin receptors [84] and activated epidermal growth 
factor receptors [85]. The intracellular fate of caveosomes, most likely, does not 
suffer in a drop in pH, and therefore the cargos can be directly transported to the 
Golgi and/or endoplasmic reticulum, avoiding normal lysosomal degradation 
[86]. 
 In order to inhibit the CvME pathway, nystatin was used, which can bind to 
cholesterol in plasma membranes and alter membrane functions, including 
caveolae formation, thus inhibiting lipid raft engulfment. 
 
1.2.1.3 Macropinocytosis (MP) 
Macropinocytosis is a type of dynamin-independent [87] fluid-phase endo-
cytosis responsible for engulfing relatively large amounts of non-specific sub-
stances [88]. MP is a signal dependent process that normally occurs in macro-
phages and cancer cells via the formation of actin-driven membrane protrusions 
which collapse onto and fuse with the plasma membrane [74]. During this 
process, Ras-related proteins in brain (Rab) are essential for the vesicle fission 
from the cell membrane [89]. Distinct from clathrin-coated vesicles and caveo-
somes, macropinosomes have no apparent coat structures and are heterogeneous 
in size, generally considered larger than 200 nm in diameter [90]. The exact 
intracellular fate of macropinosomes is unclear; it seems to be cell type 
dependent. In some cases, for example EGF-treated A431 cells, macropino-
somes do not seem to mature beyond the early endosomal stage [91], but in 
other cases late macropinosomes begin to acquire Rab7 and lysosomal glyco-
protein A (lgp-A), which are lysosome markers [92, 93]. 
 Macropinosome processing requires extensive actin remodeling that incor-
porates several acting binding proteins such as Rho-family GTPases Rac1 and 
Cdc42 [94]. Therefore cytochalasin D (CyD), which blocks actin poly-
merization, was used to inhibit macropinocytosis. In addition, macropinosome 
closure requires PI3K and this process can be inhibited by wortmannin which 
was used in this thesis as well. 
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1.2.1.4 Clathrin- and caveolin-independent endocytosis 
Clathrin- and caveolin independent endocytosis pathways are less studied as the 
formed vesicles do not possess a coat and display diverse morphology, such as 
uncoated vesicles, ring shaped structures and large tubular carriers [95, 96]. 
Clathrin- and caveolin independent endocytosis is further divided into dynamin-
dependent and independent routes and requires, similarly to caveolae-dependent 
endocytosis, lipid-rich structures for internalization. This type of endocytosis 
has been shown to internalize extracellular fluid, the B subunit of cholera toxin, 
sphingolipids, glycosylphosphatidylinositol-linked proteins, as well as receptors 
for interleukin-2, growth hormone, autocrine motility factor, endothelin, and 
many other molecules [97]. Clathrin- and caveolin-independent endocytosis is 
reliant on specific cell substituents and morphologies [73]. 
 
1.2.2 Cell membrane interaction partners 
Endocytosis of CPPs is triggered by an interaction between the peptides and the 
cell membrane. There are several potential anionic cell membrane binding part-
ners that are utilized by CPPs through electrostatic interactions and hydrogen 
bonding, such as carboxylates, phosphates and sulfates. These functional groups 
are present in cell membrane proteoglycans, phospholipids and fatty acids.  
 Proteoglycans (PG) are a heterogeneous group of proteins containing long, 
linear, polysulphated and negatively charged glycosaminoglycan (GAG) poly-
saccharides. The most prevalent GAGs in PGs are chondroitin sulphate (CS), 
dermatan sulphate (DS) and heparan sulphate (HS) [38]. These membrane 
constituents act as anionic acceptors for extracellular positively charged CPPs, 
ultimately leading to peptide uptake at multiple sites on the cell surface. 
 Studies using cell lines which do not produce HS or CS revealed that the 
internalization of nonaarginine was impaired [98]. Adding exogenous heparin to 
cells also produced the same effect in case of Tat(46–56) and Antp(43–58) [99], 
hCT(9–32)-br and Sweet Arrow Peptide (SAP) [100]. Calorimetric studies have 
revealed a strong affinity between nonaarginine and HS at binding stoichio-
metries close to charge neutralization [101]. In case of polyarginines, in ad-
dition to electrostatic interactions the guanidinium group of arginine is able to 
form hydrogen bonds with sulphate and carboxylate groups present in heparan 
sulphate proteoglycans (HSPGs) [102–104], which greatly enhances their 
uptake potential. Also a specific peptide motif, consisting of basic amino acids 
flanked by hydrophobic residues, has been found to interact with HSPGs [105, 
106]. The interaction between CPPs and these negatively charged cell memb-
rane constituents has been shown to induce aggregation and ligand clustering in 
such way that the CPPs are concentrated at the cell surface for subsequent inter-
nalization [104, 107]. Recently it has been shown that treating cells with 
octaarginine resulted in enhanced clustering of syndecan-4, a type I HSPG, on 
plasma membranes that led to protein kinase Cα activation and initiation of 
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macropinocytosis [108]. CPP aggregation however, does not always guarantee 
cellular uptake [109]. 
 After the initial interaction at the cell surface, CPPs can be taken up by the 
cell as the CPP-HSPG complex is enzymatically cleaved and CPP passes 
through the plasma bilayer to the cytoplasm directly or by endocytosis [110]. 
However, once the CPP-HSPG construct is in endosomes, the CPP can remain 
trapped, as the affinity of the interaction between the CPP and HSPGs 
diminishes due to cleavage of HS from the core protein by heparanases, causing 
a decrease in its anionic charge [111]. 
 The utilization of such unspecific electrostatic interactions suggest that CPPs 
are simply taking advantage of the cells natural membrane recycling mecha-
nisms as ca. 2–5% of a cell-membrane is recycled every minute [112, 113]. 
More precisely, the CPP may also simply attach to the cell surface and exploit 
inherent cell-membrane turnover to be internalized [38, 114]. 
 
1.2.3 Direct translocation 
Direct translocation involves destabilization of the cellular membrane in an 
energy- and temperature-independent manner [115]. Several mechanisms have 
been proposed which rely on the interactions between positively charged CPPs 
and negatively charged phospholipids in the plasma membrane, such as inverted 
micelle formation, adaptive translocation and pore-formation. 
 Inverted micelle formation refers to an invagination in the cell membrane as 
a result of electrostatic interactions and the subsequent interaction of hydro-
phobic residues with the membrane core [116]. Reorganization of the neigh-
boring lipids [117] leads to the formation an inverted micelle that encapsulates 
the CPPs in its interior and membrane disruption releases the peptide into the 
intracellular side. This model was first proposed for the translocation of 
penetratin [118] and since then numerous other studies have described 
membrane deformations, such as tabulation and formation of multivesicular 
structures when CPPs interact with model and cellular membranes [119, 120]. 
 Adaptive translocation is associated with arginine-rich CPPs and involves the 
guanidinium groups of arginines that form bidentate hydrogen bonds with the 
phospholipid headgroups on the cell membrane. This can mask the peptide 
charge, attenuating its polarity and enabling its adaptive diffusion into and 
across the membrane [21]. 
 The pore formation model is based on the formation of transient toroidal 
pores that can enable the passive diffusion of CPPs across the plasma 
membrane and was first observer for Tat and arginine-rich peptides [121, 122]. 
These CPPs accumulate in the outer leaflet and position between the phosphate 
and the carbon chains of the lipids causing a thinning of the bilayer. The 
subsequent attraction between the side chains of arginine and lysine and the 
phospholipid headgroups of the distal layer leads to the formation of a transient 
pore. Similar observations have also been made with other CPPs, such as TP10 
[123–125], Pbeta and Pep-1 [126]. In addition, pore formation has been 
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associated with membrane repair response, induced by calcium influx into the 
cells, where internal vesicles will fuse together and serve as a patch to reseal the 
membrane [34, 127, 128]. 
 Although most CPPs primarily utilize endocytosis in their cellular uptake, 
direct translocation certainly plays a part, especially in case of naked peptides. 
MPG [12], Tat [129], Pep [130], R9 [121] and CADY [127] have all been 
associated with endocytosis-independent uptake routes and, based on micro-
scopy observations as well as flow cytometry experiments, there seems to be a 
certain concentration threshold above which direct translocation of cationic 
CPPs is favored [131, 132]. Therefore a better description of these proposed 
mechanisms of internalization is required. 
 
1.2.4 Uptake mechanisms of CPP-cargo complexes 
The uptake mechanisms of CPP-cargo complexes, similarly to naked CPP 
uptake, depend on a myriad of factors such as the composition of the cell 
membrane, cell type, experimental conditions, CPP concentration and of course, 
the nature of the cargo [133–135]. The first step in CPP-cargo uptake involves 
interactions with membrane-associated proteoglycans. However, CPP-oligo-
nucleotide complexes form substantially larger particles than naked CPPs and 
the hydrodynamic size of the formed nanocomplexes is one of the factors that 
may determine their subsequent endosomal uptake route. As macropinosomes 
are the largest endosomal vesicles, macropinocytosis is most often associated 
with CPP-cargo complex internalization [136]. Therefore, endosomal escape of 
these complexes is crucial as was discussed in previous chapters. 
 Whereas certain CPPs can be taken up by both endocytosis and direct trans-
location [134], CPP-cargo nanoparticles mainly utilize endocytosis. One 
exception is CADY-siRNA nanocomplexes that induce transient cell membrane 
permeabilization, which is rapidly restored by cell membrane fluidity. There-
fore, the designers of this peptide propose that the major mechanism of cell 
entry for these complexes is direct translocation [127]. Endocytosis independent 
translocation was also observed in case of non-covalent siRNA-MPG8 and Pep-
3 complexes [137]. In contrast, PF6-oligonucleotide complexes are mainly 
taken up by smaller clathrin-coated pits [138] and in case of CPP mediated 
protein delivery, similarly to naked CPPs, several endocytic pathways can be 
utilized simultaneously [139, 140].  
 Recently, scavenger receptors have been linked to the uptake mechanism of 
CPP-oligonucleotide complexes [72]. These nanocomplexes become negatively 
charged upon interacting with serum proteins that electrostatically bind to the 
positively charged CPPs [141]. Scavenger receptors recognize negatively 
charged particles and are involved in the uptake of PepFects [70, 72], NickFects 
[142] and octaarginine-modified lipid nanoparticles [143]. After binding to 
scavenger receptors, the nanocomplexes are taken up by receptor-mediated 
endocytosis or traffic through the endo-lysosomal system [144], and as pre-
viously mentioned, these processes can occur simultaneously. 
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 Another proposed uptake mechanism of CPP-cargo complexes involves the 
formation of self-assembled CPPs around a CPP-cargo core, which interact with 
cell membrane proteoglycans, destabilizing the membrane and enabling sub-
sequent uptake of the cargo [38, 136, 145]. In order to determine the exact 
mechanism however, the physicochemical properties of CPP-cargo nano-
particles need to be determined and their interactions with cell- and endosomal 
membranes have to be assessed. 
 
1.3 CPP internalization kinetics 
The uptake rate of CPPs is an important factor when developing CPPs for drug 
delivery as it gives more information on their uptake routes compared to simple 
end-point studies. As discussed, CPP mediated uptake is dependent on peptide 
concentration and more importantly the nature of the delivered cargo, therefore 
the origin of a measured readout is crucial for interpreting the experimental data 
correctly. For example, uptake studies utilizing fluorescent labels do not 
distinguish between endosomally trapped and released peptides which can lead 
to misinterpretations. Therefore, measuring CPP kinetics using a suitably de-
signed assay serves as a valuable tool for assessing the effect of different cargos 
and peptide modifications on their uptake. 
 Examples of successful CPP kinetic studies include flow cytometry analysis 
utilizing fluorescein-tagged Tat, which indicate that its uptake kinetics is similar 
to the kinetics of endocytosis [146]. In Jurkat cells, radioisotope labelled Tat 
peptide also showed concentrative cell accumulation and rapid uptake kinetics 
[147]. Time course of the cellular uptake of rhodamine labelled Tat (48–60) and 
Drosophila Antennapedia (43–58) suggested that the arginine-rich basic 
peptides share a certain part of the internalization pathway [148]. This was 
clarified by internalization kinetics studies utilizing 7-nitrobenz-2-oxo-1,3-
diazol-4-yl (NBD) labelled pAntp, which suggest that the peptide enters into 
cells by a mechanism that involves both energy-dependent and independent 
processes [149]. 
 In order to emulate drug-conjugate delivery into a cell, drug release, and drug 
turnover by an intracellular target, releasable luciferin conjugates were 
developed that allow the quantification the real-time uptake of any delivery 
vector [150]. This assay was used to assess the in vivo skin uptake kinetics of 
octa-D-arginine [151]. By using an improved version of this assay, the cytosolic 
delivery kinetics measurements of eight common CPPs revealed that, based on 
those results, CPPs can be divided into fast and slow internalization groups 
[152]. The uptake of CPPs can be very rapid, with uptake half-times as low as 
2–12 min [33, 147, 148], however in the majority of cases they remain between 
20–60 min [33, 152, 153]. In the current thesis, CPP internalization mechanisms 
were studied by systematically inhibiting different endocytosis routes and 
measuring their cytosolic uptake kinetics utilizing either a quenched fluore-
scence assay (paper II) or a biological readout (paper III). 
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1.4 Characterization of CPP-cargo complexes 
Covalently formed CPP-cargo conjugates can be described by their molecular 
mass, secondary structure and other similar characteristics. The structure of 
non-covalently formed conjugates however, is much more dynamic and there-
fore their physicochemical properties must be described. Minor changes in 
parameters such as nanocomplex size and surface charge can strongly influence 
their biological interactions, pharmacological activity and safety [154]. Ac-
cording to the FDA [155], the required physicochemical studies that have to be 
performed on new nanoparticle based drugs include:  
 
 morphology of the delivery vector, 
 amount of delivery vector, 
 degradation products of the delivery vector, 
 particle size and size distribution of the nanoparticle, 
 light scattering index, 
 net surface charge of the nanoparticle, 
 amount of complexed and free drug, 
 in vitro release. 
 
In the following chapters, some of the most important parameters for CPP-
oligonucleotide nanocomplexes will be discussed. 
 
1.4.1 Characterizing CPP-cargo complexes by DLS 
One common physicochemical method for studying non-covalently formed 
CPP-cargo conjugates is dynamic light scattering which measures the hydro-
dynamic size and charge of the formed nanocomplexes. The size of these par-
ticles can be crucial to their efficacy, especially in in vivo and clinical settings, 
as biodistribution and elimination from blood circulation strongly depends on 
particle size and surface properties.  
 Rapid renal clearance and urinary excretion has been demonstrated for small 
particles with a hydrodynamic diameter below 5 nm [156]. On the other hand, 
nanoparticles with a hydrodynamic diameter of more than 200 nm typically 
exhibit rapid opsonisation and subsequent uptake by the mononuclear phago-
cytic system (MPS) and will be sequestered by liver and spleen [157, 158]. 
Opsonisation is a process by which a foreign structure becomes covered with 
opsonin proteins, thereby allowing its recognition by the MPS [155]. The 
opsonisation of CPP nanoparticles can be reduced by modifying their surface by 
certain molecules such as polyethylene glycol (PEG), which shields their charge 
and decreases unspecific interactions with plasma proteins [159]. As mentioned 
previously, smaller particles, 50–100 nm, are filtered by caveolae [160, 161] 
and CPP nanocomplexes need to be released in order to exhibit their biological 
effect. Another mechanism associated with nanocomplex uptake in vivo is the 
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enhanced permeability and retention (EPR) effect which is responsible for the 
enhanced accumulation of macromolecules in solid tumors [162, 163]. The 
inflammation and lesions of the vascular bed allow the accumulation of macro-
molecules and particles of a size between 50 and 500 nm inside the interstitial 
space. The discovery of the EPR effect has supported the formulation develop-
ment of nanoparticle systems for cancer therapy but in many cases the influence 
of this effect on systemic distribution has been overestimated. In most cases 
particles are cleared from the systemic circulation before the EPR effect can be 
utilized [155].  
 The net charge of the CPP-cargo nanocomplex, which can also be measured 
by DLS, determines its stability and circulation time, as it greatly influences its 
aggregation, opsonisation and clearance. However, it is also strongly influenced 
by environmental parameters, such as ionic strength, protein concentration and 
pH of the solute. A better indicator for the integrity of CPP nanocomplexes 
would be their pH-dependent zeta potential profile [155]. 
 In conclusion, depending on the surface charge, a particle size between 100 
and 300 nm is required for the optimization of circulation times and tumor accu-
mulation. Particles in this size range also exhibited the most efficient trans-
fection properties in in vitro conditions in papers I and IV. 
 
1.4.2 Characterizing CPP-cargo complexes by ITC 
Isothermal titration calorimetry (ITC) can be utilized to determine the thermo-
dynamic parameters of CPP binding processes. Most studies focus on inter-
actions between CPPs and their cell membrane counterparts [101, 104, 164–
169] with only a few examples of CPP-cargo interaction studies. 
 In order to elucidate CPP-cargo binding, ITC must be coupled with other 
physicochemical characterization methods. For example, the interaction 
between HIV-1 Tat(47–57) and double-stranded DNA was investigated by ITC 
and static right-angle light scattering. The results revealed that the CPP con-
denses the DNA in an exothermic fashion and the affinity of the CPP for DNA 
is 1–2 orders of magnitude higher than for extracellular heparan sulfate [170]. 
Another study focusing on the interactions between dendrimers, consisting of 
Tat, a nuclear localization signal peptide, dendritic polylysine, and salmon 
sperm DNA showed that dendrimers are forming stable complexes with DNA. 
In addition, the binding affinity and thermodynamic parameters were found to 
increase as the number of positive charges on the dendrimer increased, indi-
cating that ionic interactions were the major binding forces between the two 
molecules. Also, the binding affinity was stronger at pH 3.2 and precipitation of 
the complex was more prominent at pH 7.2 [171]. Isothermal titration calori-
metric data from a study where interactions between poly(amidoamine) 
(PAMAM) dendrimers and siRNA were studied suggested a simple binding for 
one of the dendrimers, whereas a biphasic binding was evident for others, with 
an initial exothermic binding and a secondary endothermic formation of larger 
dendriplex aggregates, followed by agglomeration [172]. Another biophysical 
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characterization study of an amphipathic peptide that mediates the uptake of 
non-covalently bound siRNA into cells and its subsequent release into the 
cytosol revealed that even though the peptide enhanced the uptake of siRNA 
into cells, no direct interaction between siRNA and peptide was observed at 
neutral pH by isothermal titration calorimetry. By applying additional endo-
somal-escape assays and cell-fractionation techniques, authors concluded that 
the peptide-mediated siRNA delivery occurs through a pH-dependent and 
conformation-specific interaction with cellular membranes and not with the 
cargo [173]. 
 The ITC studies on the binding processes between an amino-acid-pairing 
(AAP) peptide and siRNA revealed their interaction enthalpy and stoichiometry 
values. However, they were obtained based on a single-site independent model. 
In addition, the gel shift assay revealed that molar ratio 10:1 (peptide:siRNA) 
was required to form stable complexes, which further questions the use of the 
aforementioned model [174]. A recent study focusing on interactions between a 
retro-inverso dioleoylmelittin (riDOM) CPP and DNA as well as heparan 
sulfate revealed that riDOM binds tightly to DNA through an entropy-driven 
binding reaction with a microscopic binding constant and a stoichiometry of 12 
riDOM per 10 DNA base pairs. The CPP interacts less strongly with heparan 
sulfate and the authors hypothesize that depending on the concentration of 
sulfated glycosaminoglycans on the cell surface this process could compete with 
DNA binding and inhibit riDOM induced transfection [175]. ITC was also 
utilized in paper IV to determine the CPP-siRNA binding properties of two 
efficient siRNA delivery vectors in different solution conditions. 
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2. AIMS OF THE STUDY 
The objective of this thesis was to characterize the cellular internalization 
kinetics and mechanisms of CPPs and covalently or non-covalently formed 
CPP-cargo constructs. The aims included the assessment of the performance of 
kinetic assays compared to conventional single end-point studies in categorizing 
CPPs. The further goal also included assessing the importance of CPPs’ hydro-
phobicity and complex formation properties in nucleic acid delivery efficiency. 
The precise goals of each paper are described below. 
 
Paper I To assess the role of hydrophobic CPP modifications in non-
covalent CPP-oligonucleotide nanocomplex delivery. 
Paper II To determine the kinetic parameters of CPP cytosolic inter-
nalization utilizing a quenched fluorescence assay and to assess 
the effect of endocytosis inhibitors on this process in order to 
determine CPP uptake mechanisms. 
Paper III To determine the effect of endocytosis inhibitors on CPP cyto-
solic internalization kinetics profiles using a bioluminescence 
assay in order to assess CPP uptake mechanisms. 
Paper IV To study the physicochemical properties of CPP-siRNA binding 
processes in order to elucidate their cellular internalization 
mechanism. 
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3. METHODOLOGICAL CONSIDERATIONS 
The methods and materials used in the current thesis are presented in detail in 
each publication. This chapter briefly describes the principles of the used proto-
cols and why each particular method was chosen. 
 
3.1  Peptide selection and design 
In this thesis, the CPP transportan 10 (TP10) was modified with a variety of 
naturally occurring fatty acids in order to determine the impact of hydrophobi-
city on their ability to deliver splice-correcting antisense oligonucleotides. In 
addition to TP10, the uptake kinetic profiles and endocytic uptake routes of 
several other widely used CPPs (Table 2) were determined. Further, the cargo 
delivery mechanism of TP10 based CPPs NickFect51 and PepFect6 was 
assessed. 
 
 
Table 2. CPPs used in this thesis. 
CPP Application Paper Ref. 
TP10 Hydrophobic modifications, SCO delivery, uptake kinetics (quenched fluorescence, bioluminescence), ITC 
I,II,III, 
IV [7] 
M918 Uptake kinetics (quenched fluorescence, biolumine-scence) II,III [176] 
pVEC Uptake kinetics (quenched fluorescence, biolumine-scence) II,III [17] 
EB1 Uptake kinetics (bioluminescence) III [18] 
MAP Uptake kinetics (bioluminescence) III [11] 
Penetratin Uptake kinetics (bioluminescence) III [118] 
Tat Uptake kinetics (bioluminescence) III [4] 
TP10(Cys) Uptake kinetics (bioluminescence) III [7] 
PF6 siRNA delivery, ITC, DLS IV [53] 
NF51 siRNA delivery, ITC, DLS IV [69] 
 
 
In paper I, as it had previously reported that a stearoyl modification greatly 
enhances the SCO delivery efficacy of TP10 [64], fatty acids of different 
lengths and structure were conjugated to the Nα-terminus of TP10 to evaluate 
the overall effect of hydrophobicity on the delivery efficacy of a splice-cor-
recting 2´-OMe phosporothioate oligonucleotides. 
 In paper II the overall cargo delivery kinetics, with emphasis on cytoplasmic 
delivery, of three established CPPs, i.e. M918, TP10 and pVEC, were deter-
mined. The uptake kinetics were measured using a quenched fluorescence assay 
[33] with some modifications. 
 In paper III, the uptake mechanisms of eight established CPPs, including 
TP10, MAP, Tat, TP10(Cys), pVEC, M918, penetratin and EB1, were evaluated 
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using a semi-biological real-time uptake kinetics assay reported previously 
[150–152]. 
 In paper IV, the siRNA delivery ability of cell-penetrating peptides, 
NickFect51 and Pepfect6, was assessed by siRNA transfection, DLS and ITC 
experiments. These peptides were chosen for their excellent siRNA delivery 
properties [53, 69]. 
3.2  Peptide synthesis 
All peptides were synthesized by solid-phase peptide synthesis (SPPS) first 
described by Bruce Merrifield [177]. Briefly, the peptide is anchored to an 
insoluble support, a resin, which is stable to the chemical reactions carried out 
during the synthesis. The peptide is assembled in a step-wise manner by 
repeated cycles of formation of a peptide bond between the amino group and a 
Nα-protected amino acid, followed by deprotection of the temporary Nα-pro-
tecting group. At the end of the synthesis the assembled peptide is cleaved from 
the solid support. The functional groups of the amino acid side chains are pro-
tected with permanent protecting groups, which are also cleaved after 
completion of the synthesis. Presently, two permanent protective group strategies 
are being used, tert-butoxycarbonyl (Boc)/benzyl-based and the 9-fluorenyl-
methyloxycarbonyl (Fmoc)/tert-butyl-based strategy. 
 After cleavage, the peptides were purified by reverse-phase HPLC and the 
correct molecular weight was determined by matrix- assisted laser desorption/ 
ionization-time of flight mass spectrometry. 
 
3.3 Covalent cargo conjugation 
In this thesis, several CPPs were chemically modified. In paper I, different fatty 
acids that are present in most eukaryotic cell membranes, were added to the N-
terminus of TP10. In paper II and III, cysteines were added to the peptide 
sequences in order to induce further modifications that enable the assessment of 
CPP internalization. Paper II utilized a quenched fluorescence assay and in 
paper III a covalently attached luciferin was used in order to determine cellular 
uptake of CPPs by measuring bioluminescence. In both papers, the cargo was 
conjugated to a CPP via a disulfide bond. This method was chosen because 
disulfide bonds are only reduced in the cytosol and therefore overestimation of 
the signal arising from extracellular or endosomally trapped conjugates is 
avoided [178]. It has been reported that the disulfide bridge is cleaved by 
glutathione, which represents the major component of the cellular redox system 
[40], and to some extent enzymes such as protein disulfide isomerase [179]. 
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3.4  Non-covalent nanoparticle formation 
In papers I and IV, a non-covalent conjugation strategy was used to assess the 
cellular uptake mechanisms of CPP-cargo complexes. Non-covalent nano-
particle formation in the CPP field was first described for pDNA delivery [180] 
and has been utilized for a wide range of negatively charged cargos [181]. Non-
covalent complexes are formed by electrostatic and hydrophobic interactions 
and therefore do not require chemical modifications to the CPP or cargo. In the 
current thesis, CPPs were mixed with SCOs or siRNA for 1 h at different molar 
ratios (MRs) to determine the delivery efficacy of modified TP10 analogues in 
paper I and to assess PF6 and NF51 mediated siRNA downregulation efficacy 
in paper IV. 
3.5  Nanoparticle characterization 
In order to understand the delivery mechanism of non-covalent nanoparticles, 
several physicochemical parameters have to be described. In this thesis, the 
particle size and binding of CPP-cargo complexes in different solution condi-
tions was studied. 
 
3.5.1  Dynamic light scattering 
DLS is a spectroscopic technique which measures the fluctuations in light-
scattering intensity as a function of time over time scales from approximately 
100 ns to 30 ms. Those fluctuations are due to the Brownian motion of the 
scattering particles. The time scale of the scattering fluctuations is directly 
related to the translational diffusion coefficient of the scattering particles in the 
solvent, which in turn is related to their hydrodynamic diameter [182]. 
 The size and homogenicity of CPP-cargo complexes can determine their 
delivery efficacy as the nanoparticles have to obtain an optimal size in order to 
be internalized by cells. In in vitro experiments, the sizes can vary more as seen 
in paper I, but in vivo conditions require more condensed and smaller particles 
as different size nanocomplexes may target different organs and have different 
tissue distribution profiles [155]. 
 
3.5.2 Isothermal titration calorimetry 
In short, ITC measures the heat absorbed or released from the interaction 
between a ligand and a receptor. ITC enables the determination of binding 
affinities (Ka), stoichiometry of the binding (n) and also the enthalpy (ΔH), 
entropy (ΔS) and Gibbs free energy changes (ΔG). ITC was used in paper IV to 
elucidate CPP-siRNA binding processes by measuring the heat output when 
positively charged CPPs interact with negatively charged siRNA.  
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3.6 Cell cultures 
Three different cell lines were used in this thesis. Regular HeLa cells were used 
in paper II. HeLa cells are immortalized cervical cancer cells taken from 
Henrietta Lacks in 1951. These cells have shown high durability and versatility 
in research and have been used for applications such as drug discovery, study of 
viruses, cancer research and are also widely used in the field of CPPs. In paper I 
and III a modified HeLa cell line, HeLa pLuc 705 was used. This cell line is 
stably transfected with a luciferase-encoding gene interrupted by a mutated β-
globin intron 2 [183]. This mutation introduces an aberrant pre-mRNA splicing 
site, and thereby leads to the synthesis of nonfunctional luciferase. However, 
binding of the complementary 2′-O-Me RNA (pLuc 705 SCO) to the aberrant 
splicing site restores the normal pre-mRNA splicing and functional luciferase is 
expressed as shown in paper I (Figure 2A). 
 In paper IV we evaluated siRNA mediated gene silencing in U87 cells stably 
expressing Luc2. The U-87 MG-Luc2 cell line is a luciferase expressing 
glioblastoma cell line stably transfected with firefly luciferase gene (Luc2 vector). 
3.7  Transfection experiments 
In papers I and IV, the nucleic acid delivery efficacy of various CPPs was 
estimated by using either pLuc 705 SCOs or Luc2-silencing siRNA, respecti-
vely. Additionally, a luciferase encoding plasmid was used in paper III to in-
duce transient luciferase expression. 
 
 
Figure 2. Transfection assays used in this thesis. (A) CPPs were used to deliver pLuc 
705 antisense oligonucleotides which restore luciferase expression into cells. The 
luciferase-encoding gene is interrupted by an aberrant pre-mRNA splicing site which 
results in the synthesis of non-functional luciferase. By introducing a pLuc 705 SCO, 
luciferase expression is restored. (B) CPPs were used to deliver Luc2-silencing siRNA 
into cells stably expressing luciferase. Once reaching the cytosol, siRNA is incorporated 
into the RISC complex which selectively binds to Luc2 mRNA, degrades it and leads to 
the downregulation of protein expression. 
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3.7.1 SCO delivery 
In paper I HeLa pLuc 705 cells were utilized to assess CPP mediated cellular 
delivery efficiency of splice-correcting antisense oligonucleotides (SCOs). This 
assay is widely used as a positive read-out method for quantifying SCO delivery 
by various delivery vectors. 
 
3.7.2 siRNA delivery 
In paper IV, U-87 MG-Luc2 reporter cell line was used to compare the delivery 
efficiency of two established CPPs. By downregulating luciferase expression, 
the decreased luciferase activity can be normalized to untreated cells and gene 
silencing efficacy can be measured (Figure 2B). In order to compare different 
CPPs, measurements were performed at different CPP to siRNA molar ratios.  
 
3.8 Measuring CPP uptake kinetics 
Traditionally, CPP uptake mechanisms are measured using static endpoint as-
says. Because different CPPs internalize into cells at different rates, certain 
aspects of their cell entry mechanism could therefore be overlooked. CPP up-
take kinetics studies can serve as a valuable tool in describing their uptake 
mechanisms. 
 In the current thesis, two different methods were used in order to describe the 
cytosolic uptake of CPPs. In paper II, a quenched fluorescence assay was 
utilized, consisting of CPP and cargo. Both were modified with a cysteine 
residue, enabling covalent conjugation and a quencher-fluorophore pair was in-
corporated into the system. The cargo was carrying a fluorophore while a 
corresponding fluorescence quencher was attached to the CPP. Once reaching 
the cytosol, the disulfide bond would be cleaved leading to separation of the 
fluorophore and the quencher which in turn leads to an increase in fluorescence 
(Figure 3A). Therefore, this assay can be used to quantify CPP uptake kinetics 
in cells using a spectrofluorometer. 
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Figure 3. Uptake kinetics assays used in this thesis. (A) In the quenched fluorescence 
assay, once reaching the cytoplasm, the quencher (DNP) and fluorophore (Abz) are 
separated and fluorescence is produced. (B) In the bioluminescence assay, luciferin is 
conjugated to CPPs through a self-cyclicizing linker. Once reaching the cytoplasm, 
luciferin is released and converted to oxyluciferin by luciferase and light is emitted.  
 
In paper III, this method was improved by incorporating luciferin as the cargo. 
A spacer was chemically attached to luciferin which could be covalently con-
jugated to a cysteine residue on CPPs via a disulfide bridge. The luciferin linker 
was designed so once reaching the cytoplasm, the disulfide bridge would be 
cleaved and the spacer self-cyclicizes, allowing the release of free luciferin 
(Figure 3B). Next, the luciferin is oxidized by luciferase enzyme, emitting a 
photon of light which can be quantified at any time-point using a luminometer. 
This method has several advantages over the method used in paper II. Firstly, 
any complication arising from incomplete quenching are avoided. This assay is 
also semi-biological and can be used in adherent cells either stably or transiently 
transfected with a luciferase gene. 
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3.9 Uptake pathway studies  
utilizing endocytosis inhibitors 
Cellular internalization mechanisms can determine the trafficking and ultima-
tely, the intracellular fate of CPPs [184]. Therefore it is important to study 
which endocytic routes CPPs use for cellular internalization. In this thesis, 
several commonly used endocytosis inhibitors were utilized to elucidate the 
uptake mechanism of CPPs. However, none of the used inhibitors of different 
uptake pathways is absolutely specific. They either have side-effects resulting 
from affecting the actin cytoskeleton or interfering with alternative uptake 
pathways simultaneously. In paper II, chlorpromazine (10 µM), cytochalasin D 
(4 µM), wortmannin (50 nM) and sucrose (0.4 M) were used whereas in paper 
III chlorpromazine (10 µM), cytochalasin D (4 µM), nystatin (50 µM) and 
chloroquine (100 µM) were used (Table 3). 
 
 
Table 3. Endocytosis inhibitors used in this thesis. 
Inhibitor Mechanism Affected pathway CME* MP* C/LR* 
Chlorpromazine Depletion of clathrin/AP2 from the cellular membrane to endosomal membranes +++ + - 
Sucrose Clathrin dispersion from the cellular membrane +++ + + 
Wortmannin Phosphoinositide metabolism (PI3K) inhibitor + +++ + 
Cytochalasin D Depolymerization of F-actin and disassembly of the actin cytoskeleton + +++ + 
Nystatin Interaction with cholesterol in the cellular membrane - - +++ 
Chloroquine Promotion of endosomal escape/slowing down overall endocytosis + + + 
* CME – clathrin mediated endocytosis; MP – macropinocytosis; C/LR – Caveolae/ 
lipid raft dependent endocytosis 
 
 
Chlorpromazine and sucrose were used to inhibit clathrin mediated endocytosis 
(CME). This pathway is named after the clathrin protein, containing heavy and 
light chains, that forms clathrin coted pits. Sucrose disperses plasma membrane 
clathrin structures and thus inhibits CME. Chlorpromazine is a cationic amphi-
pathic drug that triggers the depletion of clathrin and AP2 adaptor protein 
complex from the plasma membrane and leads to their artificial assembly on 
endosomal membranes [185]. However, both of these inhibitors also inhibit 
macropinocytosis. Furthermore, sucrose can influence the cortical actin cyto-
skeleton which can cause non-specific cytotoxicity which affects all major 
endocytic routes to some extent. Therefore, it was used only in paper II and 
together with chlorpromazine which discriminates the clathrin-mediated endo-
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cytic pathway initially and is therefore more specific [185]. That said, chlorpro-
mazine can also insert into the plasma membrane and change its fluidity. It also 
affects actin dynamics by inhibiting phospholipase C, which could influence 
macropinocytosis. 
 Cytochalasin D and wortmannin were used to inhibit macropinocytosis (MP). 
Cytochalasin D inhibits membrane ruffling and endocytosis by depolymerizing 
F-actin and disassembling the actin cytoskeleton [185]. Wortmannin inhibits 
phosphoinositide metabolism, which is needed for actin cytoskeleton reorgani-
zation. However, neither of these inhibitors is highly specific because depoly-
merizing F-actin and inhibition of phosphoinositide metabolism may also 
disrupt the other two endocytic pathways. For example, cytochalasin D is also 
used as the inhibitor for caveolae-mediated endocytosis [186]. 
 Nystatin was used to inhibit the caveolae mediated endocytic pathway. 
Nystatin is an antifungal drug that forms large aggregates upon binding to 
cholesterol [185]. This changes the shape of the caveolae and inhibits the 
binding and subsequent internalization of the lipid-raft ligand. Nystatin is 
therefore quite specific in inhibiting the caveolae pathway as is does not affect 
CME or MP. 
 Chloroquine slows down the acidification of endosomal vesicles and accu-
mulates in endosomes/lysosomes causing them to swell and disrupt by osmotic 
effects [187]. This leads to either (i) endosomal escape which increases uptake 
or (ii) slowing down the overall endocytosis pathway resulting in inhibiting the 
uptake [188]. Uptake of CPP-luciferin conjugates was measured in the presence 
of chloroquine in paper III in order to determine which of these effects prevail. 
 
3.10 Toxicity studies 
Several assays were used throughout this thesis to determine the possible 
cytotoxic effects of CPPs and CPP conjugates. In addition, in paper II the extra-
cellular thiol concentrations were determined in order to assess whether the 
conjugates are cleaved before entering cells or as a result of an outflow of 
glutathione into the extracellular media. Cells were incubated with Ellmann’s 
reagent 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) that reacts with free thiols, 
leading to the release of 3-thio-6-nitrobenzoate (TNB-), which then ionizes into 
measurable yellow TNB2-. 
 In paper I, the cytotoxicity of the designed CPPs was tested by WST-1, a cell 
viability assay that measures the metabolic activity of the mitochondria. 
 In paper III, the integrity of the cellular membrane after incubation with 
CPPs was determined by lactate dehydrogenase (LDH) assay. LDH assay is a 
rapid, fluorescent measure of the release of LDH from cells with a damaged 
membrane. LDH released into the culture medium is measured with a 10-minute 
coupled enzymatic assay that results in the conversion of resazurin into reso-
rufin, the fluorescent end product of the assay. The amount of measured reso-
rufin is proportional to the amount of released LDH and is therefore proportio-
nal to membrane leakage. 
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4. RESULTS AND DISCUSSION 
In the four papers included in this thesis (three published articles and one sub-
mitted manuscript), selected CPPs are characterized in terms of their cellular 
uptake kinetics, internalization mechanisms and cargo delivery mechanisms. In 
papers II and III, kinetic assays were used in order to determine how fast and 
efficiently and, even more importantly, by which kinetic profile CPPs are being 
internalized. The readout of these assays was based on cytosolic delivery in 
order to assess their biological availability. In paper I, several hydrophobic 
modifications were conjugated to transportan 10 in order determine how CPP 
hydrophobicity affects its ability to deliver non-covalently attached oligo-
nucleotides inside cells. In paper IV, the physicochemical properties of CPP-
siRNA binding was assessed in order to elucidate their transfection mechanism. 
In this chapter, the results obtained from each paper will be summarized and 
discussed. 
 
4.1 Hydrophobic modifications are crucial  
to transportan 10 oligonucleotide delivery efficacy  
(Paper I) 
In paper I, the cell-penetrating peptide transportan 10 (TP10) was modified with 
a variety of hydrophobic molecules in order to determine their effect on non-
covalently attached oligonucleotide delivery. Hydrophobic CPP modifications 
were first reported when stearoylation of arginine rich peptides was utilized to 
transport plasmid DNA inside cells [51]. Thereafter, stearoylated TP10 was 
used as a delivery vector for splice-correcting antisense oligonucleotides using a 
non-covalent co-incubation strategy. However, the optimal length of fatty acid 
may depend on the CPP in question [63]. For example, in case of Alexa-labelled 
octaarginine, hexanoic acid showed the highest improvement in the cellular 
uptake of CPP conjugates, whereas butanoic and decanoic acid were less 
efficient [65]. 
 In order to determine the optimal hydrophobic modification for TP10, 
various fatty acids with different chain lengths, varying from 8 carbons to 24, 
were conjugated to the peptide and the conjugates’ delivery efficacy was as-
sessed using a splice correction assay (Figure 2A). In total, 12 delivery vector 
analogues were non-covalently complexed with 2´-OMe splice-correcting 
antisense oligonucleotides and the splice correction was measured at different 
peptide-to-oligonucleotide molar ratios in serum-free and serum-containing 
media using the HeLa pLuc 705 cell line. The results showed that heptade-
canoyl modification had higher splice correction ability than stearoyl, although 
statistically it was not significant. However, the effect was obtained at a lower 
molar ratio, which indicates that the heptadecanoic acid modification could be 
more efficient in delivering SCOs. Furthermore, each vector requires a different 
molar ratio in order to achieve the highest splice correction. This suggests that 
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an optimal number of hydrophobic molecules or suitable overall hydrophobicity 
may be needed to induce the required conformation for most efficient nano-
particles. In serum-containing medium stearoyl-TP10 remained most potent but 
the overall splice correction efficiency of all conjugates was significantly 
reduced. The results showed that in order to maximize splice correction 
efficacy, the optimal hydrophobicity for TP10 can be achieved by conjugating it 
to a fatty acid containing at least 16 carbons in its tail. When the fatty acid chain 
length exceeds 22 carbons, splice correction efficiency starts to decrease again. 
 In order to determine the dependency of the uptake of these complexes on 
their size we used DLS to measure the hydrodynamic diameters of the formed 
nanoparticles. Several studies focusing on siRNA, plasmid DNA and also 
protein delivery have shown that the optimal complex size for achieving 
maximal therapeutic effect in vitro and also in vivo ranges from 70 nm to 300 
nm [155]. No correlations between the hydrophobicity of the added modi-
fication and the resulting size of the CPP-SCO nanocomplexes were observed. 
The general range for all formed nanoparticles was from 100 nm to 250 nm 
when the complexes were formed in water and 500 nm to 1 µm when in Opti-
MEM. A likely cause for bigger particles obtained in Opti-MEM could be due 
to aggregation by the components present in the reduced cellular growth media. 
This could also explain why splice correction was significantly reduced in 
serum-containing media as particles around 1 µm are proposed to be only taken 
up by macropinocytosis [90]. 
 As the increase in length of the hydrocarbon chain can potentially result in 
increased toxicity [189], the safety of the peptide oligonucleotide complexes 
was determined using the Wst-1 assay. Although the arachidoyl and behenoyl 
modifications showed slight toxicity at higher concentrations, none of the 
complexes displayed statistically significant toxicity values at their most effec-
tive molar ratios. In contrast, Lipofectamine 2000, which showed the highest 
splice correction efficiency, was also the most toxic of the tested delivery 
vectors. 
 In conclusion of Paper I, the most efficient range of hydrophobicity for TP10 
analogs for delivering oligonucleotides into cells was determined. In order to 
assess how the transfection efficacy of these particles is dependent on their size, 
the hydrodynamic diameter of the formed nanoparticles was correlated with the 
vectors’ activity. The experiments revealed that in order to induce efficient SCO 
transfection, the particle size should remain between 100–200 nm. These 
findings were utilized in the development of highly efficient non-viral gene 
therapy delivery vectors, PepFects and NickFects. 
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4.2  Quenched fluorescence assay shows  
how endocytosis inhibitors affect the kinetics  
of CPP uptake (Paper II) 
Most CPP-uptake mechanism studies employ single end-point measurements 
which can overlook crucial aspects in their mode of internalization. In Paper II, 
we assessed CPP uptake mechanisms by measuring their real-time uptake 
kinetics. In addition, the effect of endocytosis inhibitors on real-time uptake 
kinetics was quantified for the first time. In order to account for the potential 
endosomally entrapped CPP portion, a quenched fluorescence assay was em-
ployed, where only the signal arising from cytoplasmic delivery will be 
registered. 
 Measurement of Abz-Cys-LKANL-amide pentapeptide uptake kinetics me-
diated by selected CPPs was first described by Hällbrink et al. [33]. The assay 
was based on measuring the increase in fluorescence by using an energy transfer 
quenching method where the Abz molecule acts as a fluorophore and nitro-
tyrosine acts as a quencher. In Paper II the side chain protective group of His, 
DNP, was used as the quencher in order to increase synthesis yields (Figure 
3A). The ability to deliver pentapeptide cargo into HeLa cells with and without 
the presence of endocytosis inhibitors of three different CPPs (M918, TP10 and 
pVEC) was assessed. The uptake kinetic curves of these conjugates were 
registered and the measured data points were fitted to one-phase exponential 
association curves according to the formula 
 
Y = Ymax · [1-exp(-K·x)]                    (Eq.1), 
 
where Y is the uptake level (pmol of internalized peptide), Ymax is the maximal 
uptake level, K is the first order constant in s-1 and x is time in s. 
 The uptake rate constants and plateau values for each CPP depend on their 
concentration but in terms of total uptake, M918 is superior to the other two, 
leaving TP10 with the lowest maximal uptake level. It is notable that a similar 
relationship does not apply to their rate constants as the values for pVEC and 
TP10 are higher than for M918 at 1 µM conjugate concentration. 
 Endocytosis inhibitors affect both the first-order rate constant and the total 
uptake level of the tested CPP conjugates. For instance, endocytosis inhibitors 
have the strongest effect on M918-mediated uptake, whereas pVEC-mediated 
uptake is less affected. Overall, there are several pathways involved in the 
uptake of these conjugates that are affected by different inhibitors in various 
extents. In case of M918, all the inhibitors lowered the total uptake, whereas 
wortmannin and sucrose increased the rate constant. In case of TP10, the total 
uptake is lowered and rate constant increased by Cpz, wortmannin and sucrose 
while CyD does not affect the rate constant but slightly increases total uptake. 
For pVEC, only sucrose lowers the total uptake and increases its rate constant. 
Overall the data revealed that the main uptake routes of M918 and pVEC 
include both macropinocytosis and CME and in case of TP10, the predominant 
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cellular entry route is CME. These findings are in line with previously pub-
lished reports [190–192]. 
 In conclusion of Paper II, these data demonstrate the advantages of real-time 
CPP uptake kinetics assays, as a more thorough picture of their uptake 
mechanisms is obtained. The results show that CPP concentration affects the 
kinetics and the total uptake of different CPPs to a different extent. This is an 
important observation since the majority of CPP delivery studies are single end-
point measurements, which may not take these specialties into account. The 
results obtained in this paper led to the development of a more complex CPP 
kinetic assay used in Paper III which focused on these aspects more in-depth. 
 
4.3 Bioluminescence assay shows how endocytosis 
inhibitors affect CPP uptake kinetic profiles (Paper III) 
In Paper III, a bioluminescence assay (Figure 3B) was used to measure the cyto-
solic uptake kinetic profiles of eight different CPPs in the presence of endo-
cytosis inhibitors. Previous results showed that CPPs can be differentiated into 
slow and fast cellular internalization groups [152] which hinted the possibility 
of an endocytosis independent internalization route. 
 In order to determine which type of endocytosis is employed by each CPP; 
Cpz, a CME inhibitor; CyD, a MP inhibitor and Nys, a C/LR inhibitor (Table 3) 
were used. Although endocytosis inhibitors are not exclusively specific, the 
long term activation of compensatory transport pathways can be minimized [73, 
185]. The inhibitors used in paper III were chosen to minimize cross-inhibition 
effects [185]. In addition to common endocytosis inhibitors, chloroquine (CQ) 
was used, which is used to inhibit the acidification rate of early endosomes and 
to promote release of endosomally entrapped material. In addition the decrease 
in acidification is accompanied by slower vesicle recycling which could slow 
down the overall rate of endocytosis [188, 193]. CQ was used to determine 
which of these mechanisms prevails in the first 2 hours of CPP uptake. 
 First we analyzed how the used endocytosis inhibitors affect the overall 
luciferin-CPP uptake at different incubation time points – 15, 30, 60 and  
120 min. The overall cytosolic uptake of all the peptide conjugates, except 
luciferin-Tat, was affected most by CyD treatment, which indicates the involve-
ment of macropinocytosis. Also, similarly to previous reports, the overall 
uptake inhibition level may depend on both the incubation time and CPP 
conjugate concentration [194, 195]. 
 In addition to calculations performed at chosen time-points, the uptake rate 
kinetic curves of the studied CPP-luciferin conjugates were characterized. 
Results revealed that incubation with endocytosis inhibitors significantly 
changes their cellular internalization kinetics suggesting a clear involvement of 
CME and caveolae/lipid raft mediated endocytosis in their cytosolic entry. At 
higher conjugate concentrations, the involvement of caveolae/lipid raft 
mediated endocytosis in the slow uptake group peptides internalization was 
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more pronounced. Also, contrary to M918 and pVEC, CME was not involved in 
the uptake of penetratin and EB1 at lower concentrations. 
 In conclusion, paper III demonstrated that the prevailing uptake route in the 
cytosolic delivery of luciferin-CPP conjugates is macropinocytosis, even for the 
fast internalizing group of peptides (MAP, Tat, TP10). In accordance with 
literature, to a smaller extent, CME and caveolae/lipid-raft dependent endo-
cytosis are involved as well. Furthermore, based on uptake kinetic data analysis, 
the involvement of different endocytosis sub-types may depend on luciferin-
CPP concentration in case of certain CPPs but not in case of others. The 
involvement of these pathways in the cytosolic luciferin-CPP delivery was 
determined when comparing the overall total uptake in selected time points but 
they are more clearly revealed when analyzing the kinetic parameters and 
shapes of the uptake kinetics curves which reflects the importance of CPP 
uptake kinetic studies. The information about the intracellular fate of CPPs is 
valuable for designing novel peptide-based delivery vectors because the 
incorporated endocytosis route and uptake kinetics might define the fate of the 
internalized material and its subsequent intracellular trafficking [155]. 
 
4.4 Physicochemical characterization of non-covalently 
formed CPP-siRNA nanocomplexes elucidates their 
cellular uptake mechanism (Paper IV) 
The end goal of CPPs is the delivery of bioactive cargos into cells. In order to 
achieve this, the uptake mechanism of CPP-cargo complexes needs to be 
elucidated. In paper IV, the non-covalent complex formation of two efficient 
siRNA transfection vectors, PF6 [53] and NF51 [69], was studied. 
 In order to determine siRNA transfection efficacy of these CPPs, different 
CPP to siRNA molar ratios (MRs) were used to form the complexes. Maximal 
siRNA-mediated target gene downregulation for each CPP was reached at MR 
20, while PF6 showed 60% downregulation already at MR 3, whereas the same 
efficacy with NF51 was reached at MR 6. This indicated that although both 
CPPs are efficient in delivering siRNA at higher MRs, there could be differen-
ces in their mechanism of action, both in terms of particle formation and inter-
action with cell membranes. 
 To study the physicochemical properties of the PF nanocomplexes, their 
hydrodynamic particle size was measured at different MRs by DLS in milliQ 
water (MQ) and at physiological pH 7.5. Results revealed that in case of both 
CPPs, in water, at lower MRs the particles were 200–300 nm in size and 
reached 100 nm after MR 10, which indicates that the nanocomplexes became 
condensed once the required CPP concentration was reached. At pH 7.5 the 
same result was achieved at MR 20. This indicated that internalized PF6- and 
NF51-siRNA nanoparticles undergo pH-dependent structure changes. In 
addition, DLS measurements performed with naked CPPs revealed that PF6 and 
NF51 form larger particles at pH 7.5 than at pH 5.0. Also, naked PF6 became 
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more compact at higher concentrations whereas NF51 particles remained 
unchanged. 
 One of the most difficult steps in characterizing CPP internalization is their 
endosomal release. In light of the latter data, we sought to investigate more 
thoroughly whether the CPP-siRNA complexes are different at physiological 
and acidic pH, thereby mimicking extracellular and endosomal conditions. 
Based on the data gathered by DLS, ITC studies were performed where the 
released heat from the interaction between the CPPs and siRNA was measured. 
Results revealed that at both endosomal pH 5.0 and physiological pH 7.5, CPPs 
bind siRNA. The data correlated with DLS data as no heat was released after 
CPP MR 10 in MQ and at pH 5.0. In case of pH 7.5, the same affect was 
obtained after MR 20, indicating again that the formation of a stable 
nanocomplex requires higher CPP concentrations. These results also correlate 
with the siRNA transfection results as maximum mRNA downregulation was 
reached at MR 20 in case of both CPPs. 
 Based on these results, we propose that PF6- and NF51-siRNA nano-
complexes are dynamic systems composed of a layer of CPPs that encapsulate 
siRNA and a second layer of CPPs that are responsible for membrane inter-
actions. Once reaching the acidic environment of endosomes, this second self-
assembled CPP layer destabilizes due to increased charge repulsion within the 
layer caused by changes in pH and enables the escape and subsequent cytosolic 
localization of siRNA. According to this theory, CPP-cargo complexes may not 
be as different from naked CPPs as previously considered and CPP uptake 
studies could also give valuable insights into their internalization mechanisms. 
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5. CONCLUSIONS 
This thesis characterizes the uptake mechanism of several commonly used 
CPPs. In addition, this thesis focuses on the cellular internalization mechanisms 
of non-covalent CPP-cargo nanocomplexes. The key findings of this thesis are 
listed below. 
 
Paper I In this paper we aimed to determine the impact of different hydro-
phobic modifications on transportan 10 for splice-correcting anti-
sense oligonucleotide delivery. We determined the optimal required 
CPP hydrophobicity and CPP-SCO nanocomplex size range for 
maximal splice correction efficacy. 
Paper II In this paper we proved that studying the uptake kinetic data pro-
vides a more thorough picture of CPP internalization compared to 
end-point assays. Endocytosis inhibitors affected both the first-order 
rate constant and the total uptake level of the CPP uptake kinetic 
curves. 
Paper III In this work, we showed that in case of certain CPPs the involvement 
of different endocytosis sub-types may depend on CPP con-
centration. In addition, we demonstrated that the main uptake route 
in the cytosolic delivery of CPP conjugates is macropinocytosis and 
to a smaller extent, CME and caveolae/lipid-raft dependent endo-
cytosis are involved as well 
Paper IV In this work we determined that CPP to siRNA molar ratio 20 is 
required for efficient siRNA transfection. In addition, physico-
chemical studies revealed that at physiological pH 7.5, MR 20 is re-
quired in order to form a condensed nanoparticle with 100 nm 
hydrodynamic range and only MR 10 is required at endosomal pH 
5.0. 
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SUMMARY IN ESTONIAN 
Rakku sisenevate peptiidide mehhanismide uurimine: 
peptiididest transpordini 
 
Aastatepikkune molekulaar- ja biokeemia areng koos inimese genoomi sekve-
neerimisprojektiga on oluliselt suurendanud meie arusaama paljude haiguste 
mehhanismidest ning on aidanud tuvastada mitmeid haigustega seotud geene. 
Nende haiguste raviks võib kasutada geeniteraapiat, mis seisneb geeni ekspres-
siooni inhibeerimises, vigase geeni väljavahetamises või geeni transportimises 
soovitud rakkudesse. Kuna paljud ravimimolekulid ei ole ise võimelised rakku-
desse sisenema, tuleb kasutada transportmolekule, mis jagunevad viirusel 
põhinevateks ja mitte-viiruslikeks. Viirustel põhinevad transporterid on efek-
tiivsed, kuid omavad tihti kõrvaltoimeid. Enim uuritud mitte-viiruslikud ravi-
mite transportvektorid põhinevad hüdrofoobsetel süsteemidel, nagu liposoomid, 
polümeerid ja mitsellid. Viimasel ajal on üha enam hakatud kasutama rakku-
desse sisenevaid peptiide (RSP), mis on võimelised transportima rakkudesse 
efektiivselt ja ilma kõrvaltoimeteta erinevaid bioloogiliselt aktiivseid molekule, 
alates madalmolekulaarsetest ravimitest kuni kõrge molekulmassiga negatiivselt 
laetud nukleiinhapeteni. 
 Alates nende avastamisest 20 aastat tagasi on loodud üle saja erineva RSP, 
mis erinevad üksteisest füsikokeemiliste omaduste ja rakkudesse sisenemise 
mehhanismide poolest. Selleks, et sõeluda välja kõige efektiivsemad transport-
vektorid on vajalik välja selgitada nende täpne sisenemismehhanism, sisenemis-
kineetika ja teised molekulide transpordi efektiivsust määravad omadused. 
 RSP-de rakku transportimises osalevad mitmed erinevad mehhanismid, mille 
kasutuse ulatus oleneb paljudest erinevatest asjaoludest, sealhulgas RSP tüüp ja 
kontsentratioon, transporditava molekuli tüüp, uuritava raku membraani 
struktuur, rakusisene sihtmärk ning muud katsetingimused. Samuti on kindlaks 
tehtud, et mitu mehhanismi võivad olla aktiivsed samaaegselt. 
 Antud töös uuriti mitme laialdaselt kasutatava RSP rakkudesse sisenemise 
mehhanisme kasutades fluorestsentsil ja bioluminestsentsil põhinevaid mee-
todeid, mis võimaldavad määrata RSP-de tsütoplasmasse jõudmise kineetikat. 
Lisaks uuriti, kuidas mõjutavad hüdrofoobsed interaktsioonid ja nanoosakeste 
omadused RSP-de võimet transportida erinevaid nukleiinhappeid rakkudesse. 
 Koos kasutati nii RSP-de rakkudesse sisenemise kineetika määramist 
võimaldavaid meetodeid kui ka lähenemist, mille abil saab hinnata, millist 
endotsütoosi rada antud RSP rakku sisenemiseks vajab. Kahe meetodi koostöö 
tulemusel saab detailsemat informatsiooni RSP-de sisenemise mehhanismide 
kohta kui lihtsamate lõpppunkti mõõtmistega, kuna sama lõpptulemust omavad 
RSP-d võivad omada täiesti erinevaid kineetilisi profiile. Leidsime, et endo-
tsütoosi radade inhibeerimine mõjutab nii üldist rakku sisenemise taset kui ka 
kineetilist profiili. Iga uuritud RSP puhul oli mõju ulatus erinev. Samuti selgus, 
et valitud peptiidide rakku sisenemise profiil võib olla väga erinev, sõltudes 
RSP kontsentratsioonist ja endotsütoosi inhibiitoritest. Mõlemad tulemused 
45 
näitavad, et nende peptiidide rakku sisenemisel on samaaegselt kasutuses mitu 
endotsütoosi rada. 
 RSP-de abil on võimalik suure molekulmassiga negatiivselt laetud nukleiin-
happeid pakkida kindla suurusega nanoosakestesse. Kuna need kompleksid 
moodustuvad läbi mitte-kovalentsete sidemete, määrati ka nende füsiko-
keemilised omadused. Uuriti, kuidas mõjutavad erinevad hüdrofoobsed modi-
fikatsioonid RSP transportan 10 võimet transportida rakkudesse splaissingut 
muutvaid oligonukleotiide. Määrati moodustunud osakeste suurus ning RSP 
hüdrofoobsuse vahemik, kus oligonukleotiidide transport on kõige efektiivsem. 
 Et teha kindlaks, kuidas moodustuvad RSP-siRNA nanokompleksid, määrati 
nende osakeste suurus ja moodustumisel eralduva soojuse hulk ning korreleeriti 
saadud tulemused siRNA transpordi efektiivsusega erinevatel RSP kontsent-
ratsioonidel. Viies läbi mõõtmisi nii endosoomide happelise pH kui ka raku 
füsiloogilise pH juures, selgus, et komplekside suurus ei olene pH muutusest. 
Samas varieerub RSP hulk kompleksis umbes kaks korda, millest järeldasime, 
et RSP ja siRNA vahel on dünaamiline, pH-st sõltuv, tasakaal. 
 Antud doktoritöös esitatud tulemused toovad välja RSP-de rakku sisenemise 
mehhanismide uurimisel kasutatavate kineetiliste meetodite eelised ning mitte-
kovalentselt moodustunud RSP-nukleiinhappe nanoosakeste füsikokeemiliste 
parameetrite olulisuse RSP-de aktiivsuse jaoks. Kokkuvõtvalt käsitletakse 
doktoritöös olulisi aspekte, mis on vajalikud uudsete transpordivektorite aren-
damiseks ja kasutuseks biotehnoloogilistes ning kliinilistes rakendustes.  
46 
REFERENCES 
1. Frankel, A.D. and C.O. Pabo, Cellular uptake of the tat protein from human 
immunodeficiency virus. Cell, 1988. 55(6): p. 1189–93. 
2. Joliot, A., C. Pernelle, H. Deagostini-Bazin, and A. Prochiantz, Antennapedia 
homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci U S A, 
1991. 88(5): p. 1864–8. 
3. Derossi, D., A.H. Joliot, G. Chassaing, and A. Prochiantz, The third helix of the 
Antennapedia homeodomain translocates through biological membranes. J Biol 
Chem, 1994. 269(14): p. 10444–50. 
4. Vivés, E., P. Brodin, and B. Lebleu, A truncated HIV-1 Tat protein basic domain 
rapidly translocates through the plasma membrane and accumulates in the cell 
nucleus. Journal of Biological Chemistry, 1997. 272(25): p. 16010–16017. 
5. Morris, M.C., L. Chaloin, J. Mery, F. Heitz, and G. Divita, A novel potent strategy 
for gene delivery using a single peptide vector as a carrier. Nucleic Acids Res, 
1999. 27(17): p. 3510–7. 
6. Morris, M.C., J. Depollier, J. Mery, F. Heitz, and G. Divita, A peptide carrier for 
the delivery of biologically active proteins into mammalian cells. Nat Biotechnol, 
2001. 19(12): p. 1173–6. 
7. Soomets, U., M. Lindgren, X. Gallet, M. Hällbrink, A. Elmquist, L. Balaspiri, M. 
Zorko, M. Pooga, R. Brasseur, and Ü. Langel, Deletion analogues of transportan. 
Biochim Biophys Acta, 2000. 1467(1): p. 165–76. 
8. Futaki, S., T. Suzuki, W. Ohashi, T. Yagami, S. Tanaka, K. Ueda, and Y. Sugiura, 
Arginine-rich peptides. An abundant source of membrane-permeable peptides 
having potential as carriers for intracellular protein delivery. J Biol Chem, 2001. 
276(8): p. 5836–40. 
9. Wender, P.A., D.J. Mitchell, K. Pattabiraman, E.T. Pelkey, L. Steinman, and J.B. 
Rothbard, The design, synthesis, and evaluation of molecules that enable or 
enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S 
A, 2000. 97(24): p. 13003–8. 
10. Lindgren, M., K. Rosenthal-Aizman, K. Saar, E. Eiriksdottir, Y. Jiang, M. Sassian, 
P. Ostlund, M. Hällbrink, and Ü. Langel, Overcoming methotrexate resistance in 
breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem 
Pharmacol, 2006. 71(4): p. 416–25. 
11. Oehlke, J., A. Scheller, B. Wiesner, E. Krause, M. Beyermann, E. Klauschenz, M. 
Melzig, and M. Bienert, Cellular uptake of an alpha-helical amphipathic model 
peptide with the potential to deliver polar compounds into the cell interior non-
endocytically. Biochim Biophys Acta, 1998. 1414(1–2): p. 127–39. 
12. Crombez, L., G. Aldrian-Herrada, K. Konate, Q.N. Nguyen, G.K. McMaster, R. 
Brasseur, F. Heitz, and G. Divita, A new potent secondary amphipathic cell-
penetrating peptide for siRNA delivery into mammalian cells. Mol Ther, 2009. 
17(1): p. 95–103. 
13. Lehto, T., R. Abes, N. Oskolkov, J. Suhorutsenko, D.M. Copolovici, I. Mäger, J.R. 
Viola, O.E. Simonson, K. Ezzat, P. Guterstam, E. Eriste, C.I.E. Smith, B. Lebleu, 
S. EL Andaloussi, and Ü. Langel, Delivery of nucleic acids with a stearylated 
(RxR)(4) peptide using a non-covalent co-incubation strategy. Journal of 
Controlled Release, 2010. 141(1): p. 42–51. 
47 
14. Gao, S., M.J. Simon, C.D. Hue, B. Morrison, and S. Banta, An Unusual Cell 
Penetrating Peptide Identified Using a Plasmid Display-Based Functional Se-
lection Platform. Acs Chemical Biology, 2011. 6(5): p. 484–491. 
15. Gao, C., S. Mao, H.J. Ditzel, L. Farnaes, P. Wirsching, R.A. Lerner, and K.D. 
Janda, A cell-penetrating peptide from a novel pVII-pIX phage-displayed random 
peptide library. Bioorg Med Chem, 2002. 10(12): p. 4057–65. 
16. Wu, H.L., C. Albrightson, and P. Nambi, Selective inhibition of rat mesangial cell 
proliferation by a synthetic peptide derived from the sequence of the C2 region of 
PKCbeta. Peptides, 1999. 20(6): p. 675–8. 
17. Elmquist, A., M. Lindgren, T. Bartfai, and Ü. Langel, VE-cadherin-derived cell-
penetrating peptide, pVEC, with carrier functions. Exp Cell Res, 2001. 269(2): p. 
237–44. 
18. Lundberg, P., S. EL Andaloussi, T. Sutlu, H. Johansson, and Ü. Langel, Delivery of 
short interfering RNA using endosomolytic cell-penetrating peptides. Faseb 
Journal, 2007. 21(11): p. 2664–2671. 
19. Pujals, S. and E. Giralt, Proline-rich, amphipathic cell-penetrating peptides. Adv 
Drug Deliv Rev, 2008. 60(4–5): p. 473–84. 
20. Abes, R., H.M. Moulton, P. Clair, S.T. Yang, S. Abes, K. Melikov, P. Prevot, D.S. 
Youngblood, P.L. Iversen, L.V. Chernomordik, and B. Lebleu, Delivery of steric 
block morpholino oligomers by (R-X-R)(4) peptides: structure-activity studies. 
Nucleic Acids Research, 2008. 36(20): p. 6343–6354. 
21. Wender, P.A., W.C. Galliher, E.A. Goun, L.R. Jones, and T.H. Pillow, The design 
of guanidinium-rich transporters and their internalization mechanisms. Adv Drug 
Deliv Rev, 2008. 60(4–5): p. 452–72. 
22. Magzoub, M., K. Kilk, L.E. Eriksson, Ü. Langel, and A. Gräslund, Interaction and 
structure induction of cell-penetrating peptides in the presence of phospholipid 
vesicles. Biochim Biophys Acta, 2001. 1512(1): p. 77–89. 
23. Ziegler, A., Thermodynamic studies and binding mechanisms of cell-penetrating 
peptides with lipids and glycosaminoglycans. Adv Drug Deliv Rev, 2008. 60(4–5): 
p. 580–97. 
24. Verdurmen, W.P.R. and R. Brock, Biological responses towards cationic peptides 
and drug carriers. Trends in Pharmacological Sciences, 2011. 32(2): p. 116–124. 
25. Nakase, I., M. Niwa, T. Takeuchi, K. Sonomura, N. Kawabata, Y. Koike, M. Take-
hashi, S. Tanaka, K. Ueda, J.C. Simpson, A.T. Jones, Y. Sugiura, and S. Futaki, 
Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin 
rearrangement. Mol Ther, 2004. 10(6): p. 1011–22. 
26. Watkins, C.L., P. Brennan, C. Fegan, K. Takayama, I. Nakase, S. Futaki, and A.T. 
Jones, Cellular uptake, distribution and cytotoxicity of the hydrophobic cell 
penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide 
PAD. Journal of Controlled Release, 2009. 140(3): p. 237–244. 
27. Pooga, M., M. Hällbrink, M. Zorko, and Ü. Langel, Cell penetration by 
transportan. FASEB J, 1998. 12(1): p. 67–77. 
28. Vie, V., N. Van Mau, L. Chaloin, E. Lesniewska, C. Le Grimellec, and F. Heitz, 
Detection of peptide-lipid interactions in mixed monolayers, using isotherms, 
atomic force microscopy, and fourier transform infrared analyses. Biophys J, 2000. 
78(2): p. 846–56. 
29. Van Mau, N., V. Vie, L. Chaloin, E. Lesniewska, F. Heitz, and C. Le Grimellec, 
Lipid-induced organization of a primary amphipathic peptide: a coupled AFM-
monolayer study. J Membr Biol, 1999. 167(3): p. 241–9. 
48 
30. Deshayes, S., K. Konate, G. Aldrian, F. Heitz, and G. Divita, Interactions of amphi-
pathic CPPs with model membranes. Methods Mol Biol, 2011. 683: p. 41–56. 
31. Nekhotiaeva, N., A. Elmquist, G.K. Rajarao, M. Hällbrink, Ü. Langel, and L. 
Good, Cell entry and antimicrobial properties of eukaryotic cell-penetrating 
peptides. FASEB J, 2004. 18(2): p. 394–6. 
32. Ghibaudi, E., B. Boscolo, G. Inserra, E. Laurenti, S. Traversa, L. Barbero, and R.P. 
Ferrari, The interaction of the cell-penetrating peptide penetratin with heparin, 
heparansulfates and phospholipid vesicles investigated by ESR spectroscopy. J Pept 
Sci, 2005. 11(7): p. 401–9. 
33. Hällbrink, M., A. Floren, A. Elmquist, M. Pooga, T. Bartfai, and Ü. Langel, Cargo 
delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta, 2001. 
1515(2): p. 101–9. 
34. Palm-Apergi, C., A. Lorents, K. Padari, M. Pooga, and M. Hällbrink, The memb-
rane repair response masks membrane disturbances caused by cell-penetrating 
peptide uptake. Faseb Journal, 2009. 23(1): p. 214–223. 
35. Lebleu, B., H.M. Moulton, R. Abes, G.D. Ivanova, S. Abes, D.A. Stein, P.L. 
Iversen, A.A. Arzumanov, and M.J. Gait, Cell penetrating peptide conjugates of 
steric block oligonucleotides. Advanced Drug Delivery Reviews, 2008. 60(4–5): p. 
517–529. 
36. Aubry, S., B. Aussedat, D. Delaroche, C.Y. Jiao, G. Bolbach, S. Lavielle, G. Chas-
saing, S. Sagan, and F. Burlina, MALDI-TOF mass spectrometry: A powerful tool 
to study the internalization of cell-penetrating peptides. Biochimica Et Biophysica 
Acta-Biomembranes, 2010. 1798(12): p. 2182–2189. 
37. Lelle, M., S.U. Frick, K. Steinbrink, and K. Peneva, Novel cleavable cell-pene-
trating peptide-drug conjugates: synthesis and characterization. J Pept Sci, 2014. 
38. Pujals, S., J. Fernandez-Carneado, C. Lopez-Iglesias, M.J. Kogan, and E. Giralt, 
Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of 
CPP self-assembly. Biochim Biophys Acta, 2006. 1758(3): p. 264–79. 
39. Saito, G., J.A. Swanson, and K.D. Lee, Drug delivery strategy utilizing conjugation 
via reversible disulfide linkages: role and site of cellular reducing activities. Adv 
Drug Deliv Rev, 2003. 55(2): p. 199–215. 
40. Bauhuber, S., C. Hozsa, M. Breunig, and A. Gopferich, Delivery of nucleic acids 
via disulfide-based carrier systems. Adv Mater, 2009. 21(32–33): p. 3286–306. 
41. Jalota-Badhwar, A., R. Kaul-Ghanekar, D. Mogare, R. Boppana, K.M. Paknikar, 
and S. Chattopadhyay, SMAR1-derived P44 peptide retains its tumor suppressor 
function through modulation of p53. J Biol Chem, 2007. 282(13): p. 9902–13. 
42. Schwarze, S.R., A. Ho, A. Vocero-Akbani, and S.F. Dowdy, In vivo protein trans-
duction: Delivery of a biologically active protein into the mouse. Science, 1999. 
285(5433): p. 1569–1572. 
43. Ezzat, K., S. EL Andaloussi, R. Abdo, and U. Langel, Peptide-based matrices as 
drug delivery vehicles. Curr Pharm Des, 2010. 16(9): p. 1167–78. 
44. Henke, E., J. Perk, J. Vider, P. de Candia, Y. Chin, D.B. Solit, V. Ponomarev, L. 
Cartegni, K. Manova, N. Rosen, and R. Benezra, Peptide-conjugated antisense 
oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat 
Biotechnol, 2008. 26(1): p. 91–100. 
45. Fei, L., L. Ren, J.L. Zaro, and W.C. Shen, The influence of net charge and charge 
distribution on cellular uptake and cytosolic localization of arginine-rich peptides. 
J Drug Target, 2011. 19(8): p. 675–80. 
49 
46. Jiang, T., E.S. Olson, Q.T. Nguyen, M. Roy, P.A. Jennings, and R.Y. Tsien, Tumor 
imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl 
Acad Sci U S A, 2004. 101(51): p. 17867–72. 
47. Malerba, A., J.K. Kang, G. McClorey, A.F. Saleh, L. Popplewell, M.J. Gait, M.J. 
Wood, and G. Dickson, Dual Myostatin and Dystrophin Exon Skipping by 
Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a 
Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dys-
trophy. Mol Ther Nucleic Acids, 2012. 1: p. e62. 
48. Deuss, P.J., A.A. Arzumanov, D.L. Williams, and M.J. Gait, Parallel synthesis and 
splicing redirection activity of cell-penetrating peptide conjugate libraries of a 
PNA cargo. Org Biomol Chem, 2013. 11(43): p. 7621–30. 
49. Khafagy, E.S. and M. Morishita, Oral biodrug delivery using cell-penetrating 
peptide. Advanced Drug Delivery Reviews, 2012. 64(6): p. 531–539. 
50. Lee, S.H., B. Castagner, and J.C. Leroux, Is there a future for cell-penetrating 
peptides in oligonucleotide delivery? European Journal of Pharmaceutics and 
Biopharmaceutics, 2013. 85(1): p. 5–11. 
51. Futaki, S., W. Ohashi, T. Suzuki, M. Niwa, S. Tanaka, K. Ueda, H. Harashima, and 
Y. Sugiura, Stearylated arginine-rich peptides: a new class of transfection systems. 
Bioconjug Chem, 2001. 12(6): p. 1005–11. 
52. Shiraishi, T. and P.E. Nielsen, Enhanced delivery of cell-penetrating peptide-
peptide nucleic acid conjugates by endosomal disruption. Nature Protocols, 2006. 
1(2): p. 633–636. 
53. Andaloussi, S.E., T. Lehto, I. Mäger, K. Rosenthal-Aizman, Oprea, II, O.E. Simon-
son, H. Sork, K. Ezzat, D.M. Copolovici, K. Kurrikoff, J.R. Viola, E.M. Zaghloul, 
R. Sillard, H.J. Johansson, F. Said Hassane, P. Guterstam, J. Suhorutsenko, P.M. 
Moreno, N. Oskolkov, J. Halldin, U. Tedebark, A. Metspalu, B. Lebleu, J. Lehtio, 
C.I. Smith, and Ü. Langel, Design of a peptide-based vector, PepFect6, for efficient 
delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res, 2011. 
39(9): p. 3972–87. 
54. Ren, Y., S. Hauert, J.H. Lo, and S.N. Bhatia, Identification and Characterization of 
Receptor-Specific Peptides for siRNA Delivery. Acs Nano, 2012. 6(10): p. 8620–
8631. 
55. Ren, Y., H.W. Cheung, G. von Maltzhan, A. Agrawal, G.S. Cowley, B.A. Weir, 
J.S. Boehm, P. Tamayo, A.M. Karst, J.F. Liu, M.S. Hirsch, J.P. Mesirov, R. 
Drapkin, D.E. Root, J. Lo, V. Fogal, E. Ruoslahti, W.C. Hahn, and S.N. Bhatia, 
Targeted Tumor-Penetrating siRNA Nanocomplexes for Credentialing the Ovarian 
Cancer Oncogene ID4. Science Translational Medicine, 2012. 4(147). 
56. Kosuge, M., T. Takeuchi, I. Nakase, A.T. Jones, and S. Futaki, Cellular inter-
nalization and distribution of arginine-rich peptides as a function of extracellular 
peptide concentration, serum, and plasma membrane associated proteoglycans. 
Bioconjugate Chemistry, 2008. 19(3): p. 656–664. 
57. Youngblood, D.S., S.A. Hatlevig, J.N. Hassinger, P.L. Iversen, and H.M. Moulton, 
Stability of cell-penetrating peptide-morpholino oligomer conjugates in human 
serum and in cells. Bioconjugate Chemistry, 2007. 18(1): p. 50–60. 
58. Wyman, T.B., F. Nicol, O. Zelphati, P.V. Scaria, C. Plank, and F.C. Szoka, Design, 
synthesis, and characterization of a cationic peptide that binds to nucleic acids and 
permeabilizes bilayers. Biochemistry, 1997. 36(10): p. 3008–3017. 
59. Kumar, P., H.Q. Wu, J.L. McBride, K.E. Jung, M.H. Kim, B.L. Davidson, S.K. 
Lee, P. Shankar, and N. Manjunath, Transvascular delivery of small interfering 
RNA to the central nervous system. Nature, 2007. 448(7149): p. 39–43. 
50 
60. Teesalu, T., K.N. Sugahara, V.R. Kotamraju, and E. Ruoslahti, C-end rule peptides 
mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proceedings 
of the National Academy of Sciences of the United States of America, 2009. 
106(38): p. 16157–16162. 
61. Wang, F., Y. Wang, X. Zhang, W. Zhang, S. Guo, and F. Jin, Recent progress of 
cell-penetrating peptides as new carriers for intracellular cargo delivery. J Control 
Release, 2014. 174: p. 126–36. 
62. Kim, H.J., A. Ishii, K. Miyata, Y. Lee, S.R. Wu, M. Oba, N. Nishiyama, and K. 
Kataoka, Introduction of stearoyl moieties into a biocompatible cationic poly-
aspartamide derivative, PAsp(DET), with endosomal escaping function for en-
hanced siRNA-mediated gene knockdown. Journal of Controlled Release, 2010. 
145(2): p. 141–148. 
63. Dasgupta, P., A. Singh, and R. Mukherjee, N-terminal acylation of somatostatin 
analog with long chain fatty acids enhances its stability and anti-proliferative 
activity in human breast adenocarcinoma cells. Biol Pharm Bull, 2002. 25(1): p. 
29–36. 
64. Mäe, M., S. EL Andaloussi, P. Lundin, N. Oskolkov, H.J. Johansson, P. Guterstam, 
and Ü. Langel, A stearylated CPP for delivery of splice correcting oligonucleotides 
using a non-covalent co-incubation strategy. J Control Release, 2009. 134(3): p. 
221–7. 
65. Katayama, S., H. Hirose, K. Takayama, I. Nakase, and S. Futaki, Acylation of 
octaarginine: Implication to the use of intracellular delivery vectors. Journal of 
Controlled Release, 2011. 149(1): p. 29–35. 
66. Hoyer, J. and I. Neundorf, Knockdown of a G protein-coupled receptor through 
efficient peptide-mediated siRNA delivery. Journal of Controlled Release, 2012. 
161(3): p. 826–834. 
67. Lee, J.S. and C.H. Tung, Enhanced cellular uptake and metabolic stability of lipo-
oligoarginine peptides. Biopolymers, 2011. 96(6): p. 772–9. 
68. Lee, J.S. and C.H. Tung, Lipo-oligoarginines as effective delivery vectors to 
promote cellular uptake. Molecular Biosystems, 2010. 6(10): p. 2049–2055. 
69. Arukuusk, P., L. Pärnaste, N. Oskolkov, D.M. Copolovici, H. Margus, K. Padari, 
K. Moll, J. Maslovskaja, R. Tegova, G. Kivi, A. Tover, M. Pooga, M. Ustav, and 
Ü. Langel, New generation of efficient peptide-based vectors, NickFects, for the 
delivery of nucleic acids. Biochim Biophys Acta, 2013. 1828(5): p. 1365–73. 
70. Lindberg, S., A. Munoz-Alarcon, H. Helmfors, D. Mosqueira, D. Gyllborg, O. 
Tudoran, and Ü. Langel, PepFect15, a novel endosomolytic cell-penetrating 
peptide for oligonucleotide delivery via scavenger receptors. Int J Pharm, 2013. 
441(1–2): p. 242–7. 
71. Ezzat, K., S. EL Andaloussi, E.M. Zaghloul, T. Lehto, S. Lindberg, P.M. Moreno, 
J.R. Viola, T. Magdy, R. Abdo, P. Guterstam, R. Sillard, S.M. Hammond, M.J. 
Wood, A.A. Arzumanov, M.J. Gait, C.I. Smith, M. Hällbrink, and Ü. Langel, 
PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in 
solution and as solid formulation. Nucleic Acids Res, 2011. 39(12): p. 5284–98. 
72. Ezzat, K., H. Helmfors, O. Tudoran, C. Juks, S. Lindberg, K. Padari, S. EL Anda-
loussi, M. Pooga, and Ü. Langel, Scavenger receptor-mediated uptake of cell-
penetrating peptide nanocomplexes with oligonucleotides. FASEB J, 2012. 26(3): 
p. 1172–80. 
73. Doherty, G.J. and H.T. McMahon, Mechanisms of endocytosis. Annu Rev Bio-
chem, 2009. 78: p. 857–902. 
51 
74. Hillaireau, H. and P. Couvreur, Nanocarriers' entry into the cell: relevance to drug 
delivery. Cellular and Molecular Life Sciences, 2009. 66(17): p. 2873–2896. 
75. Aderem, A. and D.M. Underhill, Mechanisms of phagocytosis in macrophages. 
Annu Rev Immunol, 1999. 17: p. 593–623. 
76. Xiang, S., H. Tong, Q. Shi, J.C. Fernandes, T. Jin, K. Dai, and X. Zhang, Uptake 
mechanisms of non-viral gene delivery. J Control Release, 2012. 158(3): p. 371–8. 
77. Rappoport, J.Z., Focusing on clathrin-mediated endocytosis. Biochem J, 2008. 
412(3): p. 415–23. 
78. Takei, K. and V. Haucke, Clathrin-mediated endocytosis: membrane factors pull 
the trigger. Trends Cell Biol, 2001. 11(9): p. 385–91. 
79. Wieffer, M., T. Maritzen, and V. Haucke, SnapShot: Endocytic Trafficking. Cell, 
2009. 137(2). 
80. Luzio, J.P., M.D. Parkinson, S.R. Gray, and N.A. Bright, The delivery of endo-
cytosed cargo to lysosomes. Biochem Soc Trans, 2009. 37(Pt 5): p. 1019–21. 
81. Mukherjee, S., R.N. Ghosh, and F.R. Maxfield, Endocytosis. Physiol Rev, 1997. 
77(3): p. 759–803. 
82. Brodsky, F.M., C.Y. Chen, C. Knuehl, M.C. Towler, and D.E. Wakeham, Bio-
logical basket weaving: formation and function of clathrin-coated vesicles. Annu 
Rev Cell Dev Biol, 2001. 17: p. 517–68. 
83. Nichols, B., Caveosomes and endocytosis of lipid rafts. J Cell Sci, 2003. 116(Pt 
23): p. 4707–14. 
84. Fagerholm, S., U. Ortegren, M. Karlsson, I. Ruishalme, and P. Stralfors, Rapid 
insulin-dependent endocytosis of the insulin receptor by caveolae in primary 
adipocytes. PLoS One, 2009. 4(6): p. e5985. 
85. Ning, Y., T. Buranda, and L.G. Hudson, Activated epidermal growth factor re-
ceptor induces integrin alpha2 internalization via caveolae/raft-dependent endo-
cytic pathway. J Biol Chem, 2007. 282(9): p. 6380–7. 
86. Bengali, Z., J.C. Rea, and L.D. Shea, Gene expression and internalization following 
vector adsorption to immobilized proteins: dependence on protein identity and 
density. J Gene Med, 2007. 9(8): p. 668–78. 
87. Conner, S.D. and S.L. Schmid, Regulated portals of entry into the cell. Nature, 
2003. 422(6927): p. 37–44. 
88. Sarkar, K., M.J. Kruhlak, S.L. Erlandsen, and S. Shaw, Selective inhibition by 
rottlerin of macropinocytosis in monocyte-derived dendritic cells. Immunology, 
2005. 116(4): p. 513–24. 
89. Jones, A.T., Macropinocytosis: searching for an endocytic identity and role in the 
uptake of cell penetrating peptides. J Cell Mol Med, 2007. 11(4): p. 670–84. 
90. Swanson, J.A. and C. Watts, Macropinocytosis. Trends in Cell Biology, 1995. 
5(11): p. 424–428. 
91. West, M.A., M.S. Bretscher, and C. Watts, Distinct endocytotic pathways in epi-
dermal growth factor-stimulated human carcinoma A431 cells. J Cell Biol, 1989. 
109(6 Pt 1): p. 2731–9. 
92. Racoosin, E.L. and J.A. Swanson, Macropinosome maturation and fusion with 
tubular lysosomes in macrophages. J Cell Biol, 1993. 121(5): p. 1011–20. 
93. Falcone, S., E. Cocucci, P. Podini, T. Kirchhausen, E. Clementi, and J. Meldolesi, 
Macropinocytosis: regulated coordination of endocytic and exocytic membrane 
traffic events. J Cell Sci, 2006. 119(Pt 22): p. 4758–69. 
94. Cox, D., P. Chang, Q. Zhang, P.G. Reddy, G.M. Bokoch, and S. Greenberg, Requi-
rements for both Rac1 and Cdc42 in membrane ruffling and phagocytosis in 
leukocytes. J Exp Med, 1997. 186(9): p. 1487–94. 
52 
95. Romer, W., L. Berland, V. Chambon, K. Gaus, B. Windschiegl, D. Tenza, M.R. 
Aly, V. Fraisier, J.C. Florent, D. Perrais, C. Lamaze, G. Raposo, C. Steinem, P. 
Sens, P. Bassereau, and L. Johannes, Shiga toxin induces tubular membrane 
invaginations for its uptake into cells. Nature, 2007. 450(7170): p. 670–5. 
96. Kirkham, M., A. Fujita, R. Chadda, S.J. Nixon, T.V. Kurzchalia, D.K. Sharma, 
R.E. Pagano, J.F. Hancock, S. Mayor, and R.G. Parton, Ultrastructural identi-
fication of uncoated caveolin-independent early endocytic vehicles. J Cell Biol, 
2005. 168(3): p. 465–76. 
97. Kirkham, M. and R.G. Parton, Clathrin-independent endocytosis: new insights 
into caveolae and non-caveolar lipid raft carriers. Biochim Biophys Acta, 2005. 
1746(3): p. 349–63. 
98. Fuchs, S.M. and R.T. Raines, Pathway for polyarginine entry into mammalian 
cell. Biochemistry, 2004. 43(9): p. 2438–2444. 
99. Console, S., C. Marty, C. Garcia-Echeverria, R. Schwendener, and K. Ballmer-
Hofer, Antennapedia and HIV transactivator of transcription (TAT) "protein 
transduction domains" promote endocytosis of high molecular weight cargo upon 
binding to cell surface glycosaminoglycans. J Biol Chem, 2003. 278(37): p. 
35109–14. 
100. Foerg, C., U. Ziegler, J. Fernandez-Carneado, E. Giralt, R. Rennert, A.G. Beck-
Sickinger, and H.P. Merkle, Decoding the entry of two novel cell-penetrating 
peptides in HeLa cells: lipid raft-mediated endocytosis and endosomal escape. 
Biochemistry, 2005. 44(1): p. 72–81. 
101. Wallbrecher, R., W.P. Verdurmen, S. Schmidt, P.H. Bovee-Geurts, F. Broecker, 
A. Reinhardt, T.H. van Kuppevelt, P.H. Seeberger, and R. Brock, The stoichio-
metry of peptide-heparan sulfate binding as a determinant of uptake efficiency of 
cell-penetrating peptides. Cell Mol Life Sci, 2013. 
102. Nakase, I., T. Takeuchi, G. Tanaka, and S. Futaki, Methodological and cellular 
aspects that govern the internalization mechanisms of arginine-rich cell-
penetrating peptides. Advanced Drug Delivery Reviews, 2008. 60(4–5): p. 598–
607. 
103. Rothbard, J.B., T.C. Jessop, R.S. Lewis, B.A. Murray, and P.A. Wender, Role of 
membrane potential and hydrogen bonding in the mechanism of translocation of 
guanidinium-rich peptides into cells. J Am Chem Soc, 2004. 126(31): p. 9506–7. 
104. Goncalves, E., E. Kitas, and J. Seelig, Binding of oligoarginine to membrane 
lipids and heparan sulfate: structural and thermodynamic characterization of a 
cell-penetrating peptide. Biochemistry, 2005. 44(7): p. 2692–702. 
105. Cardin, A.D. and H.J. Weintraub, Molecular modeling of protein-glycosa-
minoglycan interactions. Arteriosclerosis, 1989. 9(1): p. 21–32. 
106. Ruoslahti, E., Proteoglycans in cell regulation. J Biol Chem, 1989. 264(23): p. 
13369–72. 
107. Ziegler, A., P. Nervi, M. Durrenberger, and J. Seelig, The cationic cell-pene-
trating peptide Cpp(TAT) derived from the HIV-1 protein TAT is rapidly 
transported into living fibroblasts: Optical, biophysical, and metabolic evidence. 
Biochemistry, 2005. 44(1): p. 138–148. 
108. Nakase, I., K. Osaki, G. Tanaka, A. Utani, and S. Futaki, Molecular interplays 
involved in the cellular uptake of octaarginine on cell surfaces and the 
importance of syndecan-4 cytoplasmic V domain for the activation of protein 
kinase Calpha. Biochem Biophys Res Commun, 2014. 
109. Verdurmen, W.P., R. Wallbrecher, S. Schmidt, J. Eilander, P. Bovee-Geurts, S. 
Fanghanel, J. Burck, P. Wadhwani, A.S. Ulrich, and R. Brock, Cell surface 
53 
clustering of heparan sulfate proteoglycans by amphipathic cell-penetrating 
peptides does not contribute to uptake. J Control Release, 2013. 170(1): p. 83–91. 
110. Belting, M., Heparan sulfate proteoglycan as a plasma membrane carrier. Trends 
in Biochemical Sciences, 2003. 28(3): p. 145–151. 
111. Fuchs, S.M. and R.T. Raines, Pathway for polyarginine entry into mammalian 
cells. Biochemistry, 2004. 43(9): p. 2438–44. 
112. Kilic, G., R.B. Doctor, and J.G. Fitz, Insulin stimulates membrane conductance in 
a liver cell line – Evidence for insertion of ion channels through a phosphoino-
sitide 3-kinase-dependent mechanism. Journal of Biological Chemistry, 2001. 
276(29): p. 26762–26768. 
113. Neuhaus, E.M. and T. Soldati, A myosin I is involved in membrane recycling from 
early endosomes. Journal of Cell Biology, 2000. 150(5): p. 1013–1026. 
114. Brooks, H., B. Lebleu, and E. Vives, Tat peptide-mediated cellular delivery: back 
to basics. Adv Drug Deliv Rev, 2005. 57(4): p. 559–77. 
115. Bechara, C. and S. Sagan, Cell-penetrating peptides: 20 years later, where do we 
stand? Febs Letters, 2013. 587(12): p. 1693–1702. 
116. Henriques, S.T., M.N. Melo, and M.A.R.B. Castanho, Cell-penetrating peptides 
and antimicrobial peptides: how different are they? Biochemical Journal, 2006. 
399: p. 1–7. 
117. Joanne, P., C. Galanth, N. Goasdoue, P. Nicolas, S. Sagan, S. Lavielle, G. Chas-
saing, C. El Amri, and I.D. Alves, Lipid reorganization induced by membrane-
active peptides probed using differential scanning calorimetry. Biochim Biophys 
Acta, 2009. 1788(9): p. 1772–81. 
118. Derossi, D., S. Calvet, A. Trembleau, A. Brunissen, G. Chassaing, and A. Pro-
chiantz, Cell internalization of the third helix of the Antennapedia homeodomain 
is receptor-independent. J Biol Chem, 1996. 271(30): p. 18188–93. 
119. Lamaziere, A., F. Burlina, C. Wolf, G. Chassaing, G. Trugnan, and J. Ayala-San-
martin, Non-metabolic membrane tubulation and permeability induced by 
bioactive peptides. PLoS One, 2007. 2(2): p. e201. 
120. Hirose, H., T. Takeuchi, H. Osakada, S. Pujals, S. Katayama, I. Nakase, S. 
Kobayashi, T. Haraguchi, and S. Futaki, Transient focal membrane deformation 
induced by arginine-rich peptides leads to their direct penetration into cells. Mol 
Ther, 2012. 20(5): p. 984–93. 
121. Herce, H.D., A.E. Garcia, J. Litt, R.S. Kane, P. Martin, N. Enrique, A. Rebolledo, 
and V. Milesi, Arginine-Rich Peptides Destabilize the Plasma Membrane, 
Consistent with a Pore Formation Translocation Mechanism of Cell-Penetrating 
Peptides. Biophysical Journal, 2009. 97(7): p. 1917–1925. 
122. Herce, H.D. and A.E. Garcia, Molecular dynamics simulations suggest a mecha-
nism for translocation of the HIV-1 TAT peptide across lipid membranes. 
Proceedings of the National Academy of Sciences of the United States of 
America, 2007. 104(52): p. 20805–20810. 
123. Barany-Wallje, E., J. Gaur, P. Lundberg, Ü. Langel, and A. Gräslund, Differential 
membrane perturbation caused by the cell penetrating peptide Tp10 depending on 
attached cargo. FEBS Lett, 2007. 581(13): p. 2389–93. 
124. Yandek, L.E., A. Pokorny, A. Floren, K. Knoelke, U. Langel, and P.F. Almeida, 
Mechanism of the cell-penetrating peptide transportan 10 permeation of lipid 
bilayers. Biophys J, 2007. 92(7): p. 2434–44. 
125. Almeida, P.F. and A. Pokorny, Mechanisms of antimicrobial, cytolytic, and cell-
penetrating peptides: from kinetics to thermodynamics. Biochemistry, 2009. 
48(34): p. 8083–93. 
54 
126. Deshayes, S., T. Plenat, P. Charnet, G. Divita, G. Molle, and F. Heitz, Formation 
of transmembrane ionic channels of primary amphipathic cell-penetrating 
peptides. Consequences on the mechanism of cell penetration. Biochim Biophys 
Acta, 2006. 1758(11): p. 1846–51. 
127. Rydstrom, A., S. Deshayes, K. Konate, L. Crombez, K. Padari, H. Boukhaddaoui, 
G. Aldrian, M. Pooga, and G. Divita, Direct Translocation as Major Cellular 
Uptake for CADY Self-Assembling Peptide-Based Nanoparticles. Plos One, 2011. 
6(10). 
128. Lorents, A., P.K. Kodavali, N. Oskolkov, Ü. Langel, M. Hällbrink, and M. Pooga, 
Cell-penetrating Peptides Split into Two Groups Based on Modulation of Intra-
cellular Calcium Concentration. Journal of Biological Chemistry, 2012. 287(20): 
p. 16880–16889. 
129. Ter-Avetisyan, G., G. Tunnemann, D. Nowak, M. Nitschke, A. Herrmann, M. 
Drab, and M.C. Cardoso, Cell entry of arginine-rich peptides is independent of 
endocytosis. J Biol Chem, 2009. 284(6): p. 3370–8. 
130. Simeoni, F., M.C. Morris, F. Heitz, and G. Divita, Insight into the mechanism of 
the peptide-based gene delivery system MPG: implications for delivery of siRNA 
into mammalian cells. Nucleic Acids Research, 2003. 31(11): p. 2717–2724. 
131. Futaki, S., I. Nakase, A. Tadokoro, T. Takeuchi, and A.T. Jones, Arginine-rich 
peptides and their internalization mechanisms. Biochem Soc Trans, 2007. 35(Pt 
4): p. 784–7. 
132. Duchardt, F., M. Fotin-Mleczek, H. Schwarz, R. Fischer, and R. Brock, A 
comprehensive model for the cellular uptake of cationic cell-penetrating peptides. 
Traffic, 2007. 8(7): p. 848–66. 
133. Puckett, C.A. and J.K. Barton, Fluorescein redirects a ruthenium-octaarginine 
conjugate to the nucleus. J Am Chem Soc, 2009. 131(25): p. 8738–9. 
134. Jiao, C.Y., D. Delaroche, F. Burlina, I.D. Alves, G. Chassaing, and S. Sagan, 
Translocation and endocytosis for cell-penetrating peptide internalization. J Biol 
Chem, 2009. 284(49): p. 33957–65. 
135. Martin, I., M. Teixido, and E. Giralt, Intracellular fate of peptide-mediated 
delivered cargoes. Curr Pharm Des, 2013. 19(16): p. 2924–42. 
136. Nakase, I., H. Akita, K. Kogure, A. Gräslund, Ü. Langel, H. Harashima, and S. 
Futaki, Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-
penetrating peptides. Acc Chem Res, 2012. 45(7): p. 1132–9. 
137. Crombez, L., M.C. Morris, F. Heitz, and G. Divita, A non-covalent peptide-based 
strategy for ex vivo and in vivo oligonucleotide delivery. Methods Mol Biol, 2011. 
764: p. 59–73. 
138. Hassane, F.S., R. Abes, S. EL Andaloussi, T. Lehto, R. Sillard, Ü. Langel, and B. 
Lebleu, Insights into the cellular trafficking of splice redirecting oligonucleotides 
complexed with chemically modified cell-penetrating peptides. Journal of 
Controlled Release, 2011. 153(2): p. 163–172. 
139. Säälik, P., K. Padari, A. Niinep, A. Lorents, M. Hansen, E. Jokitalo, Ü. Langel, 
and M. Pooga, Protein delivery with transportans is mediated by caveolae rather 
than flotillin-dependent pathways. Bioconjug Chem, 2009. 20(5): p. 877–87. 
140. Räägel, H., P. Säälik, and M. Pooga, Peptide-mediated protein delivery-which 
pathways are penetrable? Biochim Biophys Acta, 2010. 1798(12): p. 2240–8. 
141. van Asbeck, A.H., A. Beyerle, H. McNeill, P.H.M. Bovee-Geurts, S. Lindberg, 
W.P.R. Verdurmen, M. Hällbrink, Ü. Lange, O. Heidenreich, and R. Brock, 
Molecular Parameters of siRNA-Cell Penetrating Peptide Nanocomplexes for 
Efficient Cellular Delivery. Acs Nano, 2013. 7(5): p. 3797–3807. 
55 
142. Arukuusk, P., L. Pärnaste, H. Margus, N.K. Eriksson, L. Vasconcelos, K. Padari, 
M. Pooga, and Ü. Langel, Differential endosomal pathways for radically modified 
peptide vectors. Bioconjug Chem, 2013. 24(10): p. 1721–32. 
143. Hayashi, Y., J. Yamauchi, I.A. Khalil, K. Kajimoto, H. Akita, and H. Harashima, 
Cell penetrating peptide-mediated systemic siRNA delivery to the liver. Int J 
Pharm, 2011. 419(1–2): p. 308–13. 
144. Stephen, S.L., K. Freestone, S. Dunn, M.W. Twigg, S. Homer-Vanniasinkam, J.H. 
Walker, S.B. Wheatcroft, and S. Ponnambalam, Scavenger receptors and their 
potential as therapeutic targets in the treatment of cardiovascular disease. Int J 
Hypertens, 2010. 2010: p. 646929. 
145. Crowet, J.M., L. Lins, S. Deshayes, G. Divita, M. Morris, R. Brasseur, and A. 
Thomas, Modeling of non-covalent complexes of the cell-penetrating peptide 
CADY and its siRNA cargo. Biochim Biophys Acta, 2013. 1828(2): p. 499–509. 
146. Richard, J.P., K. Melikov, E. Vives, C. Ramos, B. Verbeure, M.J. Gait, L.V. 
Chernomordik, and B. Lebleu, Cell-penetrating peptides. A reevaluation of the 
mechanism of cellular uptake. J Biol Chem, 2003. 278(1): p. 585–90. 
147. Polyakov, V., V. Sharma, J.L. Dahlheimer, C.M. Pica, G.D. Luker, and D. 
Piwnica-Worms, Novel Tat-peptide chelates for direct transduction of technetium-
99m and rhenium into human cells for imaging and radiotherapy. Bioconjug 
Chem, 2000. 11(6): p. 762–71. 
148. Suzuki, T., S. Futaki, M. Niwa, S. Tanaka, K. Ueda, and Y. Sugiura, Possible 
existence of common internalization mechanisms among arginine-rich peptides. J 
Biol Chem, 2002. 277(4): p. 2437–43. 
149. Drin, G., M. Mazel, P. Clair, D. Mathieu, M. Kaczorek, and J. Temsamani, 
Physico-chemical requirements for cellular uptake of pAntp peptide. Role of lipid-
binding affinity. Eur J Biochem, 2001. 268(5): p. 1304–14. 
150. Jones, L.R., E.A. Goun, R. Shinde, J.B. Rothbard, C.H. Contag, and P.A. Wender, 
Releasable luciferin-transporter conjugates: tools for the real-time analysis of 
cellular uptake and release. J Am Chem Soc, 2006. 128(20): p. 6526–7. 
151. Wender, P.A., E.A. Goun, L.R. Jones, T.H. Pillow, J.B. Rothbard, R. Shinde, and 
C.H. Contag, Real-time analysis of uptake and bioactivatable cleavage of 
luciferin-transporter conjugates in transgenic reporter mice. Proc Natl Acad Sci 
U S A, 2007. 104(25): p. 10340–5. 
152. Eiriksdottir, E., I. Mäger, T. Lehto, S. El Andaloussi, and Ü. Langel, Cellular 
internalization kinetics of (luciferin-)cell-penetrating peptide conjugates. 
Bioconjug Chem, 2010. 21(9): p. 1662–72. 
153. Mäger, I., E. Eiriksdottir, K. Langel, S. EL Andaloussi, and Ü. Langel, Assessing 
the uptake kinetics and internalization mechanisms of cell-penetrating peptides 
using a quenched fluorescence assay. Biochim Biophys Acta, 2010. 1798(3): p. 
338–43. 
154. Petros, R.A. and J.M. DeSimone, Strategies in the design of nanoparticles for 
therapeutic applications. Nat Rev Drug Discov, 2010. 9(8): p. 615–27. 
155. Wacker, M., Nanocarriers for intravenous injection--the long hard road to the 
market. Int J Pharm, 2013. 457(1): p. 50–62. 
156. Choi, H.S., W. Liu, P. Misra, E. Tanaka, J.P. Zimmer, B. Itty Ipe, M.G. Bawendi, 
and J.V. Frangioni, Renal clearance of quantum dots. Nat Biotechnol, 2007. 
25(10): p. 1165–70. 
157. Hoshino, Y., H. Koide, K. Furuya, W.W. Haberaecker, 3rd, S.H. Lee, T. Kodama, 
H. Kanazawa, N. Oku, and K.J. Shea, The rational design of a synthetic polymer 
56 
nanoparticle that neutralizes a toxic peptide in vivo. Proc Natl Acad Sci U S A, 
2012. 109(1): p. 33–8. 
158. Owens, D.E., 3rd and N.A. Peppas, Opsonization, biodistribution, and 
pharmacokinetics of polymeric nanoparticles. Int J Pharm, 2006. 307(1): p. 93–
102. 
159. Malhotra, M., C. Tomaro-Duchesneau, S. Saha, I. Kahouli, and S. Prakash, 
Development and characterization of chitosan-PEG-TAT nanoparticles for the 
intracellular delivery of siRNA. Int J Nanomedicine, 2013. 8: p. 2041–52. 
160. Braet, F., R. De Zanger, M. Baekeland, E. Crabbe, P. Van Der Smissen, and E. 
Wisse, Structure and dynamics of the fenestrae-associated cytoskeleton of rat 
liver sinusoidal endothelial cells. Hepatology, 1995. 21(1): p. 180–9. 
161. Yokomori, H., M. Oda, K. Yoshimura, and T. Hibi, Recent advances in liver 
sinusoidal endothelial ultrastructure and fine structure immunocytochemistry. 
Micron, 2012. 43(2–3): p. 129–34. 
162. Torchilin, V., Tumor delivery of macromolecular drugs based on the EPR effect. 
Adv Drug Deliv Rev, 2011. 63(3): p. 131–5. 
163. Maeda, H., T. Sawa, and T. Konno, Mechanism of tumor-targeted delivery of 
macromolecular drugs, including the EPR effect in solid tumor and clinical 
overview of the prototype polymeric drug SMANCS. J Control Release, 2001. 
74(1–3): p. 47–61. 
164. Quebatte, G., E. Kitas, and J. Seelig, riDOM, a cell penetrating peptide. 
Interaction with phospholipid bilayers. Biochim Biophys Acta, 2014. 1838(3): p. 
968–77. 
165. Sauder, R., J. Seelig, and A. Ziegler, Thermodynamics of lipid interactions with 
cell-penetrating peptides. Methods Mol Biol, 2011. 683: p. 129–55. 
166. Walrant, A., I. Correia, C.Y. Jiao, O. Lequin, E.H. Bent, N. Goasdoue, C. La-
combe, G. Chassaing, S. Sagan, and I.D. Alves, Different membrane behaviour 
and cellular uptake of three basic arginine-rich peptides. Biochim Biophys Acta, 
2011. 1808(1): p. 382–93. 
167. Ziegler, A. and J. Seelig, Binding and clustering of glycosaminoglycans: a 
common property of mono- and multivalent cell-penetrating compounds. Biophys 
J, 2008. 94(6): p. 2142–9. 
168. Binder, H. and G. Lindblom, Charge-dependent translocation of the Trojan 
peptide penetratin across lipid membranes. Biophys J, 2003. 85(2): p. 982–95. 
169. Ziegler, A., X.L. Blatter, A. Seelig, and J. Seelig, Protein transduction domains of 
HIV-1 and SIV TAT interact with charged lipid vesicles. Binding mechanism and 
thermodynamic analysis. Biochemistry, 2003. 42(30): p. 9185–94. 
170. Ziegler, A. and J. Seelig, High affinity of the cell-penetrating peptide HIV-1 Tat-
PTD for DNA. Biochemistry, 2007. 46(27): p. 8138–45. 
171. Coles, D.J., S. Yang, R.F. Minchin, and I. Toth, The characterization of a novel 
dendritic system for gene delivery by isothermal titration calorimetry. Bio-
polymers, 2008. 90(5): p. 651–4. 
172. Jensen, L.B., G.M. Pavan, M.R. Kasimova, S. Rutherford, A. Danani, H.M. 
Nielsen, and C. Foged, Elucidating the molecular mechanism of PAMAM-siRNA 
dendriplex self-assembly: effect of dendrimer charge density. Int J Pharm, 2011. 
416(2): p. 410–8. 
173. Bartz, R., H.H. Fan, J.T. Zhang, N. Innocent, C. Cherrin, S.C. Beck, Y. Pei, A. 
Momose, V. Jadhav, D.M. Tellers, F.Y. Meng, L.S. Crocker, L. Sepp-Lorenzino, 
and S.F. Barnett, Effective siRNA delivery and target mRNA degradation using an 
57 
amphipathic peptide to facilitate pH-dependent endosomal escape. Biochemical 
Journal, 2011. 435: p. 475–487. 
174. Jafari, M., W. Xu, S. Naahidi, B.L. Chen, and P. Chen, A New Amphipathic, 
Amino-Acid-Pairing (AAP) Peptide as siRNA Delivery Carrier: Physicochemical 
Characterization and in Vitro Uptake. Journal of Physical Chemistry B, 2012. 
116(44): p. 13183–13191. 
175. Quebatte, G., E. Kitas, and J. Seelig, riDOM, a Cell-Penetrating Peptide. 
Interaction with DNA and Heparan Sulfate. Journal of Physical Chemistry B, 
2013. 117(37): p. 10807–10817. 
176. EL Andaloussi, S., H.J. Johansson, T. Holm, and Ü. Langel, A novel cell-pene-
trating peptide, M918, for efficient delivery of proteins and peptide nucleic acids. 
Mol Ther, 2007. 15(10): p. 1820–6. 
177. Merrifield, R.B., Solid-phase peptide synthesis. Adv Enzymol Relat Areas Mol 
Biol, 1969. 32: p. 221–96. 
178. Shen, W.C., H.J. Ryser, and L. LaManna, Disulfide spacer between methotrexate 
and poly(D-lysine). A probe for exploring the reductive process in endocytosis. J 
Biol Chem, 1985. 260(20): p. 10905–8. 
179. Mercanti, V., S.J. Charette, N. Bennett, J.J. Ryckewaert, F. Letourneur, and P. 
Cosson, Selective membrane exclusion in phagocytic and macropinocytic cups. J 
Cell Sci, 2006. 119(Pt 19): p. 4079–87. 
180. Morris, M.C., P. Vidal, L. Chaloin, F. Heitz, and G. Divita, A new peptide vector 
for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids 
Res, 1997. 25(14): p. 2730–6. 
181. Alhakamy, N.A., A.S. Nigatu, C.J. Berkland, and J.D. Ramsey, Noncovalently 
associated cell-penetrating peptides for gene delivery applications. Ther Deliv, 
2013. 4(6): p. 741–57. 
182. Philo, J.S., Is any measurement method optimal for all aggregate sizes and types? 
AAPS J, 2006. 8(3): p. E564–71. 
183. Kang, S.H., M.J. Cho, and R. Kole, Up-regulation of luciferase gene expression 
with antisense oligonucleotides: implications and applications in functional assay 
development. Biochemistry, 1998. 37(18): p. 6235–9. 
184. Le, P.U. and I.R. Nabi, Distinct caveolae-mediated endocytic pathways target the 
Golgi apparatus and the endoplasmic reticulum. J Cell Sci, 2003. 116(Pt 6): p. 
1059–71. 
185. Ivanov, A.I., Pharmacological inhibition of endocytic pathways: is it specific 
enough to be useful? Methods Mol Biol, 2008. 440: p. 15–33. 
186. Parton, R.G., B. Joggerst, and K. Simons, Regulated internalization of caveolae. J 
Cell Biol, 1994. 127(5): p. 1199–215. 
187. Wattiaux, R., N. Laurent, S. Wattiaux-De Coninck, and M. Jadot, Endosomes, 
lysosomes: their implication in gene transfer. Adv Drug Deliv Rev, 2000. 41(2): 
p. 201–8. 
188. Tietze, C., P. Schlesinger, and P. Stahl, Chloroquine and ammonium ion inhibit 
receptor-mediated endocytosis of mannose-glycoconjugates by macrophages: 
apparent inhibition of receptor recycling. Biochem Biophys Res Commun, 1980. 
93(1): p. 1–8. 
189. Viola, J.R., H. Leijonmarck, O.E. Simonson, Oprea, II, R. Frithiof, P. Purhonen, 
P.M. Moreno, K.E. Lundin, R. Stromberg, and C.I. Smith, Fatty acid-spermine 
conjugates as DNA carriers for nonviral in vivo gene delivery. Gene Ther, 2009. 
16(12): p. 1429–40. 
58 
190. Lundin, P., H. Johansson, P. Guterstam, T. Holm, M. Hansen, Ü. Langel, and S. 
EL Andaloussi, Distinct uptake routes of cell-penetrating peptide conjugates. Bio-
conjug Chem, 2008. 19(12): p. 2535–42. 
191. EL Andaloussi, S., P. Järver, H.J. Johansson, and Ü. Langel, Cargo-dependent 
cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative 
study. Biochem J, 2007. 407(2): p. 285–92. 
192. Elmquist, A., M. Hansen, and Ü. Langel, Structure-activity relationship study of 
the cell-penetrating peptide pVEC. Biochim Biophys Acta, 2006. 1758(6):  
p. 721–9. 
193. Pack, D.W., A.S. Hoffman, S. Pun, and P.S. Stayton, Design and development of 
polymers for gene delivery. Nat Rev Drug Discov, 2005. 4(7): p. 581–93. 
194. Heitz, F., M.C. Morris, and G. Divita, Twenty years of cell-penetrating peptides: 
from molecular mechanisms to therapeutics. Br J Pharmacol, 2009. 157(2):  
p. 195–206. 
195. Fonseca, S.B., M.P. Pereira, and S.O. Kelley, Recent advances in the use of cell-
penetrating peptides for medical and biological applications. Adv Drug Deliv 
Rev, 2009. 61(11): p. 953–64. 
 
  
59 
ACKNOWLEDGEMENTS 
This study was carried out at the Institute of Technology at the University of Tartu and 
at the Department of Neurochemistry at Stockholm University. The work was supported 
by the Swedish Research Council (VR-NT); by the Center for Biomembrane Research, 
Stockholm; by Knut and Alice Wallenberg's Foundation; by the EU trough the Euro-
pean Regional Development Fund through the Center of Excellence in Chemical 
Biology, Estonia; by the targeted financing SF0180027s08 from the Estonian Govern-
ment; by the DoRa Program of The European Social Fund; by the Archimedes 
Foundation; by SSF (Sweden Japan); by the funds from the targeted financing IUT20–
26 from the Estonian Ministry of Education and Research; by the Estonian Science 
Foundation (ETF9438); by project HCV-Tech (3.2.0701.11–0015) and by Tumor-Tech: 
3.2.1001.11–0008. 
First of all I would like to thank my supervisor Prof. Ülo Langel. Thank you for 
believing in me and for your professional guidance. 
Secondly, I would like to thank Anders Florén for teaching me the basics of 
peptide synthesis and how to be a Swedish scientist. I would also like to thank Peter 
Järver for taking over when Anders got tired. My sincere thanks also go out to Ursel 
Soomets and Kalle Kilk for much needed advice and teaching me how to be an 
Estonian scientist. 
I would like to thank my close colleagues Imre Mäger and Taavi Lehto for being 
inspirational scientists, for always supporting me and being such good friends in 
general. 
I want to express my gratitude to all present and former co-workers from our 
group in Tartu as well: Elo Eriste, Evelin Rammul, Dana Maria Copolovici, Jaanus 
Lahe, Jekaterina Frolova, Julia Suhorutšenko, Kadi-Liis Veiman, Kadri Künnapuu, 
Kaido Kurrikoff, Kalle Pärn, Katrin Zirk, Krista Freimann, Kristina Kiisholts, Ly 
Pärnaste, Nikita Oskolkov, Piret Arukuusk and Tõnis Lehto. It has been a true 
pleasure working with you all. Special thanks go out to Indrek Saar for constantly 
motivating me with his relentless energy. 
I want to thank people from the Department of Neurochemistry in Stockholm for 
their support during my stay in Stockholm: Andrés Muños-Alarcón, Jakob Regberg, 
Johan Runesson, Kariem Ezzat, Marie-Louise Tjörnhammar, Mattias Hällbrink, 
Rania Abu Abdo, Rannar Sillard, Henrik Helmfors and Samir EL Andaloussi. I 
especially thank Staffan Lindberg for taking me under his wing and being a great 
friend. 
I would like to thank all the collaborators from other research groups that I have had 
pleasure to work with and learn from: Ago Rinken, Ale Närvänen, Andres Merits, Asko 
Uri, Jaak Järv, Mart Ustav, Matjaź Zorko and Tanel Tenson. Many thanks go to Prof. 
Margus Pooga for fruitful discussions. I would also like to thank Vasili Hauryliuk for 
teaching me how to be a Belarusian scientist. 
Finally, I would like to thank Imre, Taavi, Kaido and Piret for proof-reading the 
thesis. 
 
Siirad tänud mu sõpradele ja perele toetuse eest. 
Aitäh Merlin, et sa alati olemas oled! 
  
  
 
 
 
 
 
 
 
PUBLICATIONS 
CURRICULUM VITAE 
Name: Kent Langel 
Date of birth: 3.06.1987 
Nationality: Estonian 
Contact: Institute of Technology, University of Tartu 
  Nooruse 1, 50411, Tartu, Estonia 
E-mail:  kent.langel@gmail.com 
 
Education and employment 
1994–2006  Pärnu Koidula Gymnasium 
2006–2009  Tartu University, Chemistry, BSc 
2007–2014  University of Tartu, Institute of Technology, 
technology specialist 
2008–2010  Cepep Eesti OÜ, technology specialist 
2009–2011  Tartu University, Chemistry, MSc 
 
Special courses 
2010 Visiting MSc student in Stockholm University, Department of 
Neurochemistry 
 
List of publications 
1.  Järver, P., Langel, K., EL Andaloussi, S., and Langel, Ü. (2007) Applica-
tions of cell-penetrating peptides in regulation of gene expression. Biochem. 
Soc.Transactions, 25(4), 770–774. 
2.  Langel, K., Lindberg, S., Copolovici, D.M., Arukuusk, P., Sillard, R., Lan-
gel, Ü. (2010) Novel Fatty Acid Modifications of Transportan 10. Int.J.Pep. 
Protein Therap, Volume 16, Number 4, 247–255. 
3.  Mäger, I., Eiríksdóttir, E., Langel, K., EL Andaloussi, S., Langel, Ü. (2010). 
Assessing the uptake kinetics and internalization mechanisms of cell-pene-
trating peptides using a quenched fluorescence assay. Biochimica et Bio-
physica Acta-Biomembranes, 1798(3), 338–343. 
4.  Mäger, I., Langel, K., Lehto, T., Eiríksdóttir, E., Langel, Ü. (2012). The role 
of endocytosis on the uptake kinetics of luciferin-conjugated cell-penetrating 
peptides. Biochimica et Biophysica Acta-Biomembranes, 1818(3), 502–511. 
5.  Saar, I., Lahe, J., Langel, K., Runesson, J., Karlsson, K., Järv, J., Rytkönen, 
J., Närvänen, A., Kurrikoff, K., Langel, Ü. (2013) Novel systemically active 
galanin receptor 2 ligands in depression-like behaviour. Journal of Neuro-
chemistry. 127(1), 114–123. 
6.  Veiman, K-L., Mäger, I., Ezzat, K., Margus, H., Lehto, T., Langel, K., 
Kurrikoff, K., Arukuusk, P., Suhorutsenko, J., Padari, K., Pooga, M., Lehto, 
T., Langel, Ü. (2013) PepFect14 peptide vector for efficient gene delivery 
in cell cultures. Mol Pharm, 10(1), 199–210. 
7.  Copolovici, D.M, Langel, K., Eriste, E., and Langel, Ü. (2014) Cell-Pene-
trating Peptides: Design, Synthesis and Applications. ACS Nano. 8(3), 
1972–94. 
113 
ELULOOKIRJELDUS 
Nimi: Kent Langel 
Sünniaeg: 3.06.1987 
Kodakondsus: Eesti 
Kontaktandmed: Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, 
Tehnoloogiainstituut, Nooruse 1, 50411 Tartu, Eesti 
E-post:  kent.langel@gmail.com 
 
Haridus ja teenistuskäik: 
1994–2006  Pärnu Koidula Gümnaasium 
2006–2009  Tartu Ülikool, Keemia, BSc 
2007–2014  Tartu Ülikool, Tehnoloogiainstituut, tehnoloogia spetsialist 
2008–2010  Cepep Eesti OÜ, tehnoloogia spetsialist 
2009–2011  Tartu Ülikool, Keemia, MSc 
 
Erialane enesetäiendus: 
2010 Vahetus-magistrant Stockholmi Ülikoolis,  
Neurokeemia Instituudis 
 
Teaduspublikatsioonid 
1.  Järver, P., Langel, K., EL Andaloussi, S., and Langel, Ü. (2007) Applica-
tions of cell-penetrating peptides in regulation of gene expression. 
Biochem.Soc.Transactions, 25(4), 770–774. 
2.  Langel, K., Lindberg, S., Copolovici, D.M., Arukuusk, P., Sillard, R., 
Langel, Ü. (2010) Novel Fatty Acid Modifications of Transportan 10. 
Int.J.Pep.Protein Therap, Volume 16, Number 4, 247–255. 
3.  Mäger, I., Eiríksdóttir, E., Langel, K., EL Andaloussi, S., Langel, Ü. (2010). 
Assessing the uptake kinetics and internalization mechanisms of cell-
penetrating peptides using a quenched fluorescence assay. Biochimica et 
Biophysica Acta-Biomembranes, 1798(3), 338–343. 
4.  Mäger, I., Langel, K., Lehto, T., Eiríksdóttir, E., Langel, Ü. (2012). The role 
of endocytosis on the uptake kinetics of luciferin-conjugated cell-penetrating 
peptides. Biochimica et Biophysica Acta-Biomembranes, 1818(3), 502–511. 
5.  Saar, I., Lahe, J., Langel, K., Runesson, J., Karlsson, K., Järv, J., Rytkönen, 
J., Närvänen, A., Kurrikoff, K., Langel, Ü. (2013) Novel systemically active 
galanin receptor 2 ligands in depression-like behaviour. Journal of Neuro-
chemistry. 127(1), 114–123. 
6.  Veiman, K-L., Mäger, I., Ezzat, K., Margus, H., Lehto, T., Langel, K., 
Kurrikoff, K., Arukuusk, P., Suhorutsenko, J., Padari, K., Pooga, M., Lehto, 
T., Langel, Ü. (2013) PepFect14 peptide vector for efficient gene delivery 
in cell cultures. Mol Pharm, 10(1), 199–210. 
7.  Copolovici, D.M, Langel, K., Eriste, E., and Langel, Ü. (2014) Cell-Pene-
trating Peptides: Design, Synthesis and Applications. ACS Nano. 8(3), 
1972–94. 
114 
 DISSERTATIONES TECHNOLOGIAE 
UNIVERSITATIS TARTUENSIS 
1. Imre Mäger. Characterization of cell-penetrating peptides: Assessment of 
cellular internalization kinetics, mechanisms and bioactivity. Tartu 2011, 
132 p. 
2. Taavi Lehto. Delivery of nucleic acids by cell-penetrating peptides: appli-
cation in modulation of gene expression. Tartu 2011, 155 p.  
3. Hannes Luidalepp. Studies on the antibiotic susceptibility of Escherichia 
coli. Tartu 2012, 111 p. 
4. Vahur Zadin. Modelling the 3D-microbattery. Tartu 2012, 149 p. 
5. Janno Torop. Carbide-derived carbon-based electromechanical actuators. 
Tartu 2012, 113 p. 
6. Julia Suhorutšenko. Cell-penetrating peptides: cytotoxicity, immunogeni-
city and application for tumor targeting. Tartu 2012, 139 p. 
7.  Viktoryia Shyp. G nucleotide regulation of translational GTPases and the 
stringent response factor RelA. Tartu 2012, 105 p. 
8.  Mardo Kõivomägi. Studies on the substrate specificity and multisite 
phosphorylation mechanisms of cyclin-dependent kinase Cdk1 in Saccharo-
myces cerevisiae. Tartu, 2013, 157 p. 
9. Liis Karo-Astover. Studies on the Semliki Forest virus replicase protein 
nsP1. Tartu, 2013, 113 p. 
10.  Piret Arukuusk. NickFects–novel cell-penetrating peptides. Design and 
uptake mechanism. Tartu, 2013, 124 p.  
11. Piret Villo. Synthesis of acetogenin analogues. Asymmetric transfer hydro-
genation coupled with dynamic kinetic resolution of -amido--keto esters. 
Tartu, 2013, 151 p. 
12. Villu Kasari. Bacterial toxin-antitoxin systems: transcriptional cross-acti-
vation and characterization of a novel mqsRA system. Tartu, 2013, 108 p.  
13. Margus Varjak. Functional analysis of viral and host components of alpha-
virus replicase complexes. Tartu, 2013, 151 p. 
14.  Liane Viru. Development and analysis of novel alphavirus-based multi-
functional gene therapy and expression systems. Tartu, 2013, 113 p. 
